

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Cognitive impairment and psychopathology in Out-of-Hospital Cardiac Arrest survivors in Denmark. The REVIVAL cohort study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-038633
Article Type:	Protocol
Date Submitted by the Author:	19-Mar-2020
Complete List of Authors:	<p>Wagner, Mette; Copenhagen University Hospital, Rigshospitalet, Department of Cardiology</p> <p>Berg, Selina; Copenhagen University Hospital. Rigshospitalet , Department of Cardiology; University of Copenhagen, Department of Clinical Medicine</p> <p>Hassager, Christian; Copenhagen University Hospital, Rigshospitalet, Department of Cardiology ; University of Copenhagen, Department of Clinical Medicine</p> <p>Armand , Sophia; Copenhagen University Hospital, Rigshospitalet, Neurobiology Research Unit</p> <p>Møller, Jacob; Odense Universitetshospital, Department of Cardiology</p> <p>Ekholm, Ola; University of Southern Denmark, National Institute of Public Health</p> <p>Rasmussen, Trine; Gentofte University Hospital, Department of Cardiology</p> <p>Fisher, Patrick; Copenhagen University Hospital, Rigshospitalet, Neurobiology Research Unit and Center for Integrated Molecular Brain Imaging</p> <p>Knudsen, Gitte ; Copenhagen University Hospital, Rigshospitalet, Neurobiology Research Unit and of Center for Integrated Molecular Brain Imaging</p> <p>Stenbæk , Dea ; Copenhagen University Hospital, Rigshospitalet, Neurobiology Research Unit</p>
Keywords:	<p>MENTAL HEALTH, CARDIOLOGY, NEUROLOGY, Anxiety disorders < PSYCHIATRY, Depression & mood disorders < PSYCHIATRY, Magnetic resonance imaging < RADIOLOGY & IMAGING</p>

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Cognitive impairment and psychopathology in Out-of-Hospital Cardiac Arrest survivors in Denmark.**
5 **The REVIVAL cohort study protocol**
6
7
8
9
10

11 Wagner, Mette Kirstine¹

12 Berg, Selina Kikkenborg^{1,2}

13 Hassager, Christian^{1,2}

14 Armand, Sophia³

15 Møller, Jacob Eifer⁴

16 Ekholm, Ola⁵

17 Rasmussen, Trine Bernholdt⁶

18 Fisher, Patrick MacDonald³

19 Knudsen, Gitte Moos³

20 Stenbæk, Dea Siggaard³

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

¹Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

²Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

³Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

⁴Department of Cardiology, Odense University Hospital, Odense, Denmark

⁵National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.

⁶Department of Cardiology, Herlev & Gentofte University Hospital, Hellerup, Denmark

Correspondence to:

Mette K. Wagner, RN, MSc, Department of Cardiology, Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Email; mette.kirstine.wagner@regionh.dk

Telephone; +45 35453143

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1
The cognitive assessment

Table 2
Outcome domains, measurement instruments, time of measurement and quantity for the cardiac arrest survivors

Table 3
Outcome domains, measurement instruments and measurement time for the relatives

Figures

Figure 1
Flowchart of study assessment

Figure 2
Direct Patient Feed-back

Supplementary material 1: Description of secondary outcomes

For peer review only

ABSTRACT

INTRODUCTION: Cognitive impairment and psychopathology caused by brain hypoxia and the traumatic impact of critical illness are common in cardiac arrest survivors and can lead to negative consequences of everyday life functioning, and further impact mental health in relatives. Most studies have dealt with the mere survival rate after cardiac arrest and not with long-term consequences to mental health in cardiac arrest survivors. Importantly, we face a gap in our knowledge about suitable screening tools in the early post-arrest phase for long-term risk prediction of mental health problems. This study aims to evaluate the feasibility and efficacy of a novel screening procedure to predict risk of disabling cognitive impairment and psychopathology after cardiac arrest. Furthermore, the study aims to evaluate long-term prevalence of psychopathology in relatives.

METHODS AND ANALYSES: In this multicenter prospective cohort study, out-of-hospital cardiac arrest survivors and their relatives will be recruited. The post-arrest screening includes the Montreal Cognitive Assessment (MoCA), the Hospital Anxiety and Depression Scale (HADS), the Impact of Event Scale-Revised (IES-R) and the Acute Stress Disorder Interview (ASDI) and is conducted during hospitalisation. In a sub-sample of the patients, functional magnetic resonance imaging is done, and cortisol determination collected. At 3-months follow-up, the primary study outcomes for 200 survivors include the Danish Affective Verbal Learning Test-26 (VAMT-26), Delis-Kaplan Executive Function System tests (trail-making, colour-word interference, word and design fluency), Rey's Complex Figure and Letter-number sequencing sub-test of Wechsler Adult Intelligence Scale-IV, HADS and IES-R. For the relatives they include HADS and IES-R.

ETHICS AND DISSEMINATION: The study is approved by the local regional Research Ethics Committee (H-18046155) and the Danish Data Protection Agency (RH-2017-325, j.no.05961) and follows the latest version of the Declaration of Helsinki. The results will be published in peer-reviewed journals and may impact the follow-up of cardiac arrest survivors.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Article summary

Strength and limitations of this study

- A strength of the study is the prospective design and consistent follow-up with the use of standardised and validated measurement tools.
- A limitation of the study is the differential loss to follow-up which can introduce bias and challenge the internal validity of the study.
- A strength of the study is the multicenter approach. This will improve statistical power and generalisability of the results.
- A strength of the study is its potential to contribute to a better referral from cardiac care to targeted rehabilitation services.

INTRODUCTION

The global incidence of cardiac arrest with assumed primary cardiac cause is 55/100,000 inhabitants (1). In Europe approximately 275,000 people with all-rhythm cardiac arrests are treated by the Emergency Medical Systems (EMS) each year (2). Out-of-hospital cardiac arrest (OHCA) is a significant cause of global mortality (3). However, in recent years the survival rates have improved especially in developing countries due to advances in the chain of survival (1). At present the majority of published OHCA studies focus on the acute prehospital and intensive care treatment of OHCA sufferers. Far fewer studies have investigated the period from early recovery to long term return to everyday life. The existing literature on this period highlights two critical challenges for cardiac arrest survivors in the post-arrest recovery process, firstly diminished neurocognitive functions and secondly disabling emotional difficulties (4–8). In these survivors, long-term cognitive impairment and psychopathology constitute both a major personal and family burden, as well as a public health and economic concern (9–16).

Mild to moderate cognitive sequelae are reported in up to 50% of survivors (6,17). Transient or permanent memory loss, attention deficit and executive impairment are the most dominant cognitive impairment found in this population (5,6,18). Importantly, impaired cognitive functioning at 3-months post-arrest has been found to correlate with worse physical and mental Health-related Quality of Life (HRQoL), and not being able to return to work around the first year after OHCA (19). Cardiac-induced cerebral hypoxia cause a diffuse injury that may damage the functional integrity of the brain (20) and cause cognitive impairment (21,22). Resting state functional magnetic resonance imaging (fMRI) is an informative imaging method that assays functional integrity and level of communication within the brain (3, 11). In a recent study, patients with increased within-network and decreased between-network functional connectivity in the acute phase after cardiac arrest survival had a favorable outcome (FO) one year later compared to patients with a non-favorable outcome (nFO) (13), suggesting higher functional integrity in patients with a FO. This increased within-network functional connectivity was also observed in a smaller study of cardiac arrest patients with good outcome at hospital discharge (14). To date, no reliable cognitive screening or imaging method for use during the in-patient hospitalisation that can detect risk of long-term cognitive impairment in cardiac arrest

1
2
3 patients exist. A post-arrest screening model may contribute to prompt initiation of relevant follow-up and
4
5 targeted cognitive rehabilitation.
6
7

8
9 A cardiac arrest is a severe and traumatising life event and long-term post-arrest psychopathology is
10
11 prevalent (5,23–25). Processing near-death experiences, coping with prolonged preoccupation with somatic
12
13 symptoms and fear of a second cardiac arrest is a burden to many cardiac arrest patients (5,23). Up to 61% of
14
15 cardiac arrest patients experience anxiety, up to 45% depression and up to 27% post-traumatic stress disorder
16
17 (PTSD) (5). In particular, anxiety and depression have been found to negatively impact Health-related
18
19 Quality of Life (HRQoL) and physical health in patients up to several years after survival (26). Furthermore,
20
21 a cardiac arrest yields the highest prevalence of PTSD among cardiac disease categories (23), and PTSD is
22
23 reported to double the overall risk of mortality, recurrence of a new cardiac event, and causing long-term
24
25 diminished mental health and quality of life (8,27). Little is currently known about the role of acute
26
27 emotional reactions for developing long-term psychopathology in cardiac arrest survivors, but high acute
28
29 stress reactions in other patient populations appear to be associated with worse long-term outcomes (28–30).
30
31 Elucidating the role of acute emotional reactions may serve to support and advice the patients about future
32
33 challenges, and to initiate targeted psychological interventions.
34
35
36
37

38
39 Being the close relative of a cardiac arrest survivor can cause enduring psychological strains (31–33).
40
41 Research indicates that these psychological strains are caused by a burden of witnessing the cardiac arrest,
42
43 having to care for the patient and from the emotional stress of living with someone who is at risk of another
44
45 cardiac arrest (34). At 1-year post-arrest, 40% of the close relatives of patients with brain injury are still
46
47 experiencing a high impact of the cardiac event and display a more severe traumatic stress level than the
48
49 patient (Armand S. The acute traumatic stress response is associated with long-term post-traumatic stress in
50
51 cardiac arrest survivors and their close relatives, Unpublished, March, 2020) , and after 2 years these
52
53 caregivers show a higher level of trauma-related stress than that observed in the general population (35). As
54
55 a growing number of patients are surviving cardiac arrest it is crucial to focus more attention on
56
57 psychological challenges in relatives in the aftermath after surviving cardiac arrest.
58
59
60

1
2
3 The overall aim of the current study is therefore to evaluate and test a novel screening procedure during
4 hospitalisation for its feasibility and ability to predict at-risk patients for disabling cognitive impairment and
5 psychopathology at 3-months. The incidence of psychopathology in close relatives 3-months post-arrest will
6 also be explored. Overall, we hypothesise that the screening procedure will be feasible and able to identify
7 at-risk patients for disabling cognitive impairment and psychopathology at 3-months follow-up. In particular
8 that:
9

10
11
12
13
14
15
16 Hypothesis 1: Lower level of cognitive impairment during hospitalisation (screening) is positively associated
17 with cognitive outcome at 3-month follow-up.
18

19
20
21 Hypothesis 2: The strength of discrete resting-state networks in the brain assessed with fMRI during
22 hospitalisation (screening) is positively associated with cognitive outcome at 3-months follow-up.
23

24
25
26 Hypothesis 3: Higher level of acute emotional reactions during hospitalisation (screening) is positively
27 associated with psychopathology outcome at 3-months follow-up.
28

29
30
31 Hypothesis 4: Higher level of cognitive impairment and emotional reactions during hospitalisation in patients
32 is positively associated with psychopathology outcomes in relatives at 3-months follow-up.
33
34
35
36
37
38

39 **METHODS AND ANALYSIS**

40 41 *Study design, setting and population*

42
43
44 The REVIVAL (REcovery after cardiac arrest surVIVAL) study is designed as a multicenter, prospective
45 cohort study in which first-time out-of-hospital cardiac arrest (OHCA) survivors are followed for up to 1
46 year after the event (flowchart presented in figure 1). The study settings are three highly specialized heart
47 centers at university hospitals in Denmark: Rigshospitalet and Herlev-Gentofte Hospital in the Capital
48 Region of Denmark and Odense University Hospital, in the Southern Region of Denmark. All cardiac arrest
49 patients will be approached for study participation and approximately 250 in-hospital patients (≥ 18 years of
50 age) with a first-time OHCA admission diagnosis will be recruited. Only patients with a presumed cardiac
51 cause for their cardiac arrest will be included. Both cardiac arrests as primary and secondary diagnosis will
52
53
54
55
56
57
58
59
60

1
2
3 be included. Furthermore, the closest relatives will be identified and included during hospitalisation for a 3-
4 months follow-up. Patients are excluded if they have a serious not treatable other somatic or psychiatric
5 illness or previous cerebrovascular events or traumatic brain injury and those unable to speak and understand
6 Danish. The cognitive screening and neuropsychological testing require the patients to follow verbal
7 instructions and to see the tasks presented. Therefore, patients with solid hearing or visual impairments are
8 excluded. In a sub-study exploring resting state fMRI and stress reactivity, respectively 40 patients without
9 contraindications to MR will be included from Rigshospitalet. The REVIVAL study is described in
10 accordance with the current Strengthening the Reporting of Observational Studies in
11 Epidemiology (STROBE) statement (Guidelines for reporting observational studies) (36).
12
13
14
15
16
17
18
19
20
21
22
23

24 *Patient selection and recruitment*

25
26 All the patients and relatives are selected and recruited in the three Danish cardiology wards. OHCA
27 survivors transferred from the intensive care unit (ICU) to the ward will be included four to nine days after
28 termination of analgo-sedatives to ensure no residual sedation used during therapeutic hypothermia. The
29 survivors from the coronary care units will be included immediately after coronary intervention in cardiac
30 catheterisation laboratory (figure 1). This subgroup of cardiac arrest survivors will be included although they
31 are awake or only had a brief period of coma after admission to the hospital and presumably recover earlier
32 to their premorbid cognitive functioning than the critically ill patients. The patients and relatives at the
33 included sites follow the same protocol.
34
35
36
37
38
39
40
41
42
43
44
45

46 A trained cardiac nurse will collect most of the clinical data from the patients' charts. The same nurse will
47 approach eligible patients during hospital admission on the cardiology ward and invite them to participate in
48 the study. The patients will be assessed clinically and provided with oral as well as written information about
49 the study. The patients are given the opportunity to read and consider the study information leaflet carefully.
50 If the patients agree to participate, they will be asked to provide written informed consent in consultation
51 with their closest relative prior to inclusion. This is justified in ethical issues as some patients with cognitive
52 impairment may not feel empowered to refuse participation.
53
54
55
56
57
58
59
60

Collection of data and measures

Screening model during hospitalisation

A team of certified nurses with a background in cardiology will screen the patients. Administration and interpretation of data will take place under supervision by a trained psychologist.

Cognition: The cognitive screening is conducted using the Danish version of the *Montreal Cognitive Assessment tool* (MoCA), version 7.0 (37). The MoCA is a brief cognitive screening test designed to identify mild cognitive impairment. The MoCA covers six cognitive domains: Attention, visuospatial construction, executive functioning, memory, language and orientation (table 1), and is rated from 0-30. A cut-off ≥ 26 is considered as normal cognitive function level. In the summary score a level of education ≤ 12 years is given an extra point as education level has shown to decrease the overall score (37). The MoCA is suggested for use in the post cardiac arrest settings (38,39), however, it remains to be evaluated in a Danish patient population with possible hypoxic-ischaemic brain injury. The MoCA has shown high level of internal reliability with Cronbach's $\alpha = 0.83$ in detection of mild cognitive impairment (37).

Mood and delirium: As symptoms of delirium often are subtle but still can have an impact on cognition, the cognitive screening is initiated with a rapid clinical assessment of delirium, using 4AT scale (40).

Furthermore, the mood state and functional independence of the patients is collected (table 2). If the study nurse is in doubt regarding patients functioning, an informed nurse or relative is asked (41).

Resting state fMRI: Patients who meet inclusion criteria for MRI will undergo structural and functional brain imaging on a 3 Tesla Siemens Prisma MRI scanner at Rigshospitalet. Trained personnel will perform MRI scans; during transport and scanning, a trained nurse will monitor the patients. We will obtain high-resolution structural T1- and T2-weighted images and T2*-weighted BOLD fMRI resting state scans (~10 minutes of resting state fMRI). During resting state fMRI, patients are asked to lie still with eyes closed and let their mind wander freely. Resting state fMRI data will be processed using canonical brain imaging tools, e.g. SPM (42) and Conn (43) to establish region-to-region connectivity estimates while accounting for

1
2
3 motion, physiological and other noise sources. Resting state networks will be defined based on *a priori*
4 connectivity networks descriptions (44).
5
6
7
8

9 **Psychopathology:** Self-rated symptoms of depression and anxiety and trauma reactions will be collected
10 using the Hospital Anxiety and Depression Scale (HADS-D and HADS-A) (45), and the Impact of event
11 Scale-revised (IES-R) (46). The Hospital Anxiety and Depression Scale (HADS) is a valid and internally
12 consistent 14 items instrument to measure anxiety and depression. Each item is scored from 0-3 with a
13 summary score between 0 and 21 for either anxiety or depression. Scores of 11 and above indicate the
14 probable presence of a mood disorder. HADS has shown a mean α of 0.83 and 0.82 for the HADS-A and
15 HADS-D, respectively (47). Impact of Event Scale - revised (IES-R) measures distress caused by a traumatic
16 event is a widely used measures to assess traumatic stress symptoms with a maximum score of 88. The IES-
17 R consist of 22-items measuring subjective distress caused by a traumatic event scored on a Likert scale from
18 0 (not at all) to 4 (extremely) and includes subscales for avoidance, intrusions and hyperarousal. The IES-R
19 has shown high internal consistency with coefficient alphas ranging from 0.84 to 0.85 for avoidance, 0.87 to
20 0.92 for intrusion, and 0.79 to 0.90 for hyperarousal (46).
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **Acute Stress disorder:** The Acute Stress Disorder Structured interview (ASDI) is a 19-item clinical
38 interview which investigates the incidence and severity of acute stress responses operated as acute stress
39 disorder (ASD) in DSM-5 in the month following trauma exposure (48,49). Acute stress disorder is divided
40 into five symptom clusters: intrusive memories or revival, negative mood, dissociation, avoidance and
41 arousal. To meet the criteria for acute stress disorder, the patient must have experienced a traumatic event (in
42 this case a cardiac arrest) during the past month (criteria A) as well as the presence or deterioration of at least
43 nine symptoms independent of the associated category after the onset of episode (Criterion B), which should
44 occur within three days to one month (Criterion C) (50).
45
46
47
48
49
50
51
52
53
54
55

56 **Cortisol Awakening Response:** At the same day as the structured clinical interview (i.e. ASDI) is
57 performed, saliva samples for determination of the Cortisol Awakening Response (CAR) will be obtained
58 from eligible patients. Five samples are collected during awakening and three saliva samples will also be
59
60

1
2
3 collected during the day at 12 at 18 and at 23 o'clock. The total amount of saliva per patient is 16 ml. After
4
5 collecting the saliva, the samples will be stored and analysed at the Department of Clinical Biochemistry,
6
7 Rigshospitalet, Glostrup.
8
9

10 Sociodemographic variables and several clinical pre- and in-hospital data were obtained from electronic
11
12 medical records (see table 2).
13
14
15

16 At 3-months follow-up

17
18 The patients included at Rigshospitalet and Herlev-Gentofte Hospital will undergo a detailed and individual
19
20 neuropsychological assessment at the Neurobiology Research Unit at Rigshospitalet, and patients included at
21
22 Odense University Hospital will be assessed with a similar test battery at the University of Southern
23
24 Denmark. The cognitive assessment of the patient's cognitive functions will be given, administered and
25
26 interpreted by a clinical and trained psychologist or psychology student under supervision. The patients and
27
28 their relatives will furthermore complete a package of self-reported questionnaires.
29
30
31

32 **The neuropsychological assessment:** The tests used are a carefully selected neuropsychological test battery
33
34 comprising the same subcomponents as for the MoCA; *attention, visuospatial construction, executive*
35
36 *functioning, memory, language and orientation*. The tests used are all validated in clinical settings for a
37
38 variety of populations and have shown good test-retest reliability. To address a source of bias, all tests are
39
40 conducted by a psychologist, who is kept blind of the clinical data as well as the results of the previous brief
41
42 cognitive screening. A detailed outline of the neuropsychological tasks includes: Danish Affective Verbal
43
44 Learning Test-26 (VAMT-26) (51) and Delis-Kaplan Executive Function System tests (D-KEFS) comprising
45
46 trail-making, colour-word interference, design fluency and word fluency (52) together with the Rey's
47
48 complex figure test (53) and Letter-number sequencing test from the Wechsler Adult Intelligence Scale-IV
49
50 (WAIS-IV) (54) (table 1).
51
52
53
54

55 **Psychopathology in patients:** Furthermore, the patients will repeat the self-reported questionnaires identical
56
57 to the questionnaires completed during hospitalisation: HADS-D, HADS-A and IES-R.
58
59
60

1
2
3 **Psychopathology in relatives:** The relatives are also asked to complete the HADS-D, HADS-A and IES-R.
4
5 The questionnaires for both patients and their relatives are sent via e-mail two weeks before the 3-months
6
7 follow-up.
8
9

10 11 At 1-year follow-up

12
13 The 1-year follow-up is designed as register-based (table 2). To investigate whether baseline data are
14
15 associated with morbidity: depression, anxiety, dementia, chronic fatigue syndrome or heart failure and
16
17 with mortality and health care utilisation, the collected data will be linked with data from national
18
19 administrative registers; the Danish National Patient Register (55), the Danish Civil Registration System
20
21 (56), the Danish National Prescription Registry (57), the Danish education registers (58), and the Danish
22
23 registers on personal income and transfer payments (59).
24
25
26
27

28 *Primary and secondary study outcome measures*

29 30 *Primary outcome measures for patients*

31
32 The primary outcome is whether the patients present a favourable outcome (FO) or a non-favourable
33
34 outcome (nFO) at 3-month follow-up. To elucidate cognition and psychopathology separately, primary
35
36 outcomes will be established for each of these domains.
37
38
39

40 **Cognition:** As primary cognitive outcome the patients will be divided into two groups, FO and nFO, based
41
42 on their performance in the neuropsychological tasks. The subset with an nFO is defined as minimum 1.5
43
44 standard deviation (SD) under the norm or reference data (52,53,60,61) on minimum one test or 1 standard
45
46 deviation on two or more tests. The rest of the patients fall into the FO group.
47
48

49 **Psychopathology:** As primary psychopathology outcome the patients will be divided into two groups, FO
50
51 and nFO, based on their scores on the HADS and IES-R. The subset with an nFO is defined one or more
52
53 scores above cut-off for psychopathology on the HADS and IES-R: HADS-D and HADS-A >8 and IES-R
54
55 >24. The rest of the patients fall into the FO group.
56
57
58

59 60 *Secondary outcome measures for patients*

1
2
3 As secondary outcomes for patients are self-reported measures of sleep quality, fatigue, executive
4 functioning, and health-related quality of life at 3-months of follow-up (table 2). A detailed description of the
5 secondary outcomes is described in the supplementary material 1. Secondary outcomes for patients also
6 include register-based information of morbidity: depression, anxiety, dementia, chronic fatigue syndrome
7 or heart failure, mortality and healthcare utilisation at 1-year post-arrest (table 2).
8
9
10
11
12
13

14 15 16 *Primary outcome measures for relatives*

17 The primary outcomes for the relatives include HADS-D, HADS-A and IES-R (45,62) (table 3).
18
19

20 21 *Secondary outcome measures for relatives*

22 Secondary outcome measures for relatives include self-reported health-related quality of life, experience of
23 cognitive changes in the patient after the cardiac arrest, social support, major depression, the quality in the
24 relationship with the cardiac arrest survivor, and the extent to which the cardiac arrest is viewed as being
25 central to one's identity (table 3).
26
27
28
29
30

31 Several exploratory outcomes will also be collected (figure 1).
32
33
34
35

36 37 *Data analysis plan*

38 The collected socio-demographic data will be presented as means \pm standard deviation (SD) or percentages,
39 respectively and group differences will be calculated by t-tests (continuous data) or χ^2 (categorical data).
40
41
42

43 Appropriate regression models will be used to examine the associations between screening performance
44 during hospitalisation and the primary and secondary study outcomes. In all model's relevant covariates e.g.
45 sex, age, comorbidity, time to return of spontaneous circulation, coma duration time, time at intensive care
46 unit, time of hospitalization, etc. will be included (table 2). A formal power calculation of sample size has
47 not been performed due to the several aims and potential analyses of this study. With no comparative patient
48 groups and only few small existing studies, we aim for a sample size of 200 cardiac arrest survivors at three
49 months follow-up for the primary outcome to be statistically and clinically significant.
50
51
52
53
54
55
56
57
58
59
60

Patient and Public Involvement

As a patient involvement method, two theme-based sessions involving *direct patient feedback* have been carried out in the early pilot and design phase of the study. The aim of these sessions was to 1) identify patient preferences regarding the cognitive screening procedure (figure 2), and 2) develop the research priorities including implementation of possible changes based on the patient's feedback. Data derived from the theme-based patient feed-back sessions provides the basis for the cognitive screening procedure in the REVIVAL study. To ensure further patient involvement, we plan to engage the patients in the planning phase of disseminating the results.

ETHICS AND DISSEMINATION

There is little to no discomfort for the patients and their relatives in this study. Due to the weakened constitution of the patients, the neuropsychological test at 3-months post-arrest could be experienced as taxing and can be divided into two days. The study complies with the Declaration of Helsinki and has been approved by the Danish national committee on health research ethics (H-18046155) and the Danish Data Protection Agency (RH-2017-325, I-Suite no: 05961). Patients and their relatives will receive oral and written information about the study and inclusion will require obtained written consent for all participants before enrolment. Results from this study will be disseminated at regional, national and international conferences and in peer-reviewed journals.

Authors' contributions

Department of Cardiology, Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Copenhagen University Hospital Rigshospitalet (Wagner, Berg, and Hassager) and Neurobiology Research Unit, Rigshospitalet (Stenbæk, Fisher and Knudsen) has full access to all the data in the study and takes responsibility for the integrity of the data and the following analysis.

1
2
3 *Study concept and design:* Wagner, Berg, Hassager and Stenbæk
4

5 *Acquisition, analysis, or interpretation of data:* All authors
6

7 *Drafting of the manuscript:* Wagner and Stenbæk
8

9 *Critical revision of the manuscript for important intellectual content:* All authors
10

11 *Obtained funding:* Wagner, Berg, Hassager and Stenbæk
12

13 *Statistical analysis:* Wagner, Stenbæk and Ekholm.
14

15 *Administrative, technical, or material support:* Wagner and Stenbæk.
16

17 Furthermore, Jensen PS Database Manager at Neurobiology Research Unit, Rigshospitalet and Britt
18

19 Corfixen, Project Coordinator, clinical biochemistry department, Glostrup, Rigshospitalet.
20

21 *Study supervision:* Berg, Hassager and Stenbæk
22
23
24
25

26 **Funding statement**

27
28 The REVIVAL study is funded by independent research grants from the following non-profit or
29
30 governmental agencies: Grant 38-A2015 and grant A5638 from The Research Foundation of Copenhagen
31
32 University Hospital, Rigshospitalet, Denmark, grant 34 177 058 from The Danish Knowledge Centre for
33
34 Rehabilitation and Palliative Care (REHPA), grant 18-B-0235 from the Helsefonden, Denmark, grant 18-
35
36 R124-A8454-22099 from the Danish Heart Association, grant from both the Research Committee and from
37
38 the Research Committee in clinical nursing, The Heart Centre, Copenhagen University Hospital,
39
40 Rigshospitalet, Denmark.
41
42
43
44

45 **Competing interest statement**

46
47 On behalf of all authors, the corresponding author states that there are no conflicts of interest related to this
48
49 study. The funding sources have no role in the design and conduct of the study.
50
51
52
53
54
55
56
57
58
59
60

References

1. Porzer M, Mrazkova E, Homza M, Janout V. Out-of-hospital cardiac arrest. 2017;161(4):348–53.
2. Myat A, Song KJ, Rea T. Out-of-hospital cardiac arrest: current concepts. *Lancet*. 2018;391(10124):970–9.
3. Berdowski J, Berg RA, Tijssen JGP, Koster RW. Global incidences of out-of-hospital cardiac arrest and survival rates : Systematic review of 67 prospective studies & , &&. *Resuscitation*. 2010;81(11):1479–87.
4. Elliott VJ, Rodgers DL, Brett SJ. Systematic review of quality of life and other patient-centred outcomes after cardiac arrest survival &. *Resuscitation*. 2016;82(2011):247–56.
5. Green CR, Botha JA, Tiruvoipati R. Review Cognitive function , quality of life and mental health in survivors of out-of-hospital cardiac arrest : a review. *Anaesth Intensive Care*. 2015;43(5):568–77.
6. Moulaert VRMP, Verbunt JA, Heugten CM Van, Wade DT. Cognitive impairments in survivors of out-of-hospital cardiac arrest : A systematic review &. *Resuscitation*. 2016;80(2009):297–305.
7. Cronberg T, Lilja G, Horn J, Kjaergaard J, Wise MP, Pellis T, et al. Neurologic Function and Health-Related Quality of Life in Patients Following Targeted Temperature Management at 33°C vs 36°C After Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. *JAMA Neurol*. 2015;72:634–41.
8. Wilder Schaaf KP, Artman LK, Peberdy MA, Walker WC, Ornato JP, Gossip MR, et al. Anxiety, depression, and PTSD following cardiac arrest: A systematic review of the literature. *Resuscitation*. 2013;84(7):873–7.
9. Whitehead L, Perkins GD, Clarey a., Haywood KL. A systematic review of the outcomes reported in cardiac arrest clinical trials: THE need for a core outcome set. *Resuscitation*. 2015;88:150–7.
10. Perez C a., Samudra N, Aiyagari V. Cognitive and Functional Consequence of Cardiac Arrest. *Curr Neurol Neurosci Rep*. 2016;16:70.
11. Sakusic A, O’Horo JC, Dziadzko M, Volha D, Ali R, Singh TD, et al. Potentially Modifiable Risk Factors for Long-Term Cognitive Impairment After Critical Illness: A Systematic Review. *Mayo Clin Proc*. 2018;93(1):68–82.
12. Davies SE, Rhys M, Voss S, Greenwood R, Thomas M, Bengler JR. Psychological wellbeing in survivors of cardiac arrest, and its relationship to neurocognitive function. *Resuscitation*. 2017;
13. Wachelder EM, Moulaert VRMP, Heugten C Van. Life after survival : Long-term daily functioning and quality of life after an out-of-hospital cardiac arrest &. *Resuscitation*. 2009;80:517–22.
14. Descatha A, Dumas F, Bougouin W, Cariou A, Geri G. Work factors associated with return to work in out-of-hospital cardiac arrest survivors. *Resuscitation*. 2018;128(February 2018):170–4.
15. Lilja, Nielsen, Bro-Jeppesen, Dunford, Friberg, Hofgren, et al. Return to Work and Participation in Society After Out-of-Hospital Cardiac Arrest. *Circ Cardiovasc Qual Outcomes*. 2018;11(1):e003566.
16. Van Wijnen HGFM, Rasquin SMC, Van Heugten CM, Verbunt JA, Moulaert VRM. The impact of cardiac arrest on the long-term wellbeing and caregiver burden of family caregivers: A prospective cohort study. *Clin Rehabil*. 2017;31(9):1267–75.

17. Cronberg T, Lilja G. Cognitive decline after cardiac arrest - It is more to the picture than hypoxic brain injury. *Resuscitation*. 2015;91(2015):A3–4.
18. Journal AI, Heugten C Van, Gregório GW, Wade D, Heugten C Van, Gregório GW, et al. Evidence-based cognitive rehabilitation after acquired brain injury : A systematic review of content of treatment. 2012;2011(May 2016).
19. Moulaert VRM, Van Heugten CM, Winkens B, Bakx WGM, De Krom MCFTM, Gorgels TPM, et al. Early neurologically-focused follow-up after cardiac arrest improves quality of life at one year: A randomised controlled trial. *Int J Cardiol*. 2015;193.
20. Barkhof F, Haller S, Rombouts SARB. Resting-State Functional MR Imaging: A New Window to the Brain. *Radiology*. 2014;272(1):29–49.
21. Nolan JP, Soar J, Cariou A, Cronberg T, Moulaert VRM, Deakin CD, et al. European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for Post-resuscitation Care 2015: Section 5 of the European Resuscitation Council Guidelines for Resuscitation 2015. *Resuscitation*. 2015;95:202–22.
22. Hinduja A, Gupta H, Yang JD, Onteddu S. Hypoxic ischemic brain injury following in hospital cardiac arrest - Lessons from autopsy. *J Forensic Leg Med*. 2014;23(2014):84–6.
23. Vilchinsky N, Ginzburg K, Fait K, Foa EB. Cardiac-disease-induced PTSD (CDI-PTSD): A systematic review. *Clin Psychol Rev*. 2017;55(October 2016):92–106.
24. Gamper G, Willeit M, Sterz F, Herkner H, Zoufaly A, Hornik K, et al. Life after death: Posttraumatic stress disorder in survivors of cardiac arrest - Prevalence, associated factors, and the influence of sedation and analgesia. *Crit Care Med*. 2004;32(2):378–83.
25. Kamphuis HCM, De Leeuw JRJ, Derksen R, Hauer R, Winnubst JAM. A 12-month quality of life assessment of cardiac arrest survivors treated with or without an implantable cardioverter defibrillator. *Europace*. 2002;4(4):417–25.
26. Moulaert V, Wachelder E, Verbunt J, Wade D, van Heugten C. Determinants of quality of life in survivors of cardiac arrest. *J Rehabil Med*. 2010;42(6):553–8.
27. Edmondson D, Richardson S, Falzon L, Davidson KW, Mills MA, Neria Y. Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syndrome patients: A meta-analytic review. *PLoS One*. 2012;7(6).
28. Visser E, Gosens T, Den Oudsten BL, De Vries J. The course, prediction, and treatment of acute and posttraumatic stress in trauma patients. *J Trauma Acute Care Surg*. 2017;82(6):1158–83.
29. Bryant, R.A., M.L. Moulds and RMG. Acute Stress Disorder Scale: A Self-Report Measure of Acute Stress Disorder. *Psychol Assess*. 2000;12(1):61–8.
30. Wessa, M. et al. Altered cortisol awakening response in posttraumatic stress disorder. *Psychoneuroendocrinology*. 2006;31(2):209–15.
31. Van Wijnen HGFM, Rasquin SMC, Van Heugten CM, Verbunt JA, Moulaert VRM. The impact of cardiac arrest on the long-term wellbeing and caregiver burden of family caregivers: A prospective cohort study. *Clin Rehabil*. 2017;31(9):1267–75.
32. Zimmerli M and risk factors for post-traumatic stress disorder in relatives of out-of-hospital cardiac arrest patients, Tisljar K, Balestra GM, Langewitz W, Marsch S, Hunziker S. Prevalence and risk factors for post-traumatic stress disorder in relatives of out-of-hospital cardiac arrest patients. *Resuscitation*. 2014;

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

33. Haywood K, Dainty KN. Life after cardiac arrest: The importance of engaging with the ‘forgotten patient’. *Resuscitation*. 2018;128:A1–2.
34. Moulaert V. Life after survival of a cardiac arrest: The brain is the heart of the matter. 2014.
35. van't Wout Hofland J, Moulaert V, van Heugten C, Verbunt J. Long-term quality of life of caregivers of cardiac arrest survivors and the impact of witnessing a cardiac event of a close relative. *Resuscitation*. 2018;128(March 2018):198–203.
36. Vandembroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. *PLoS Med*. 2007;4(10):1628–54.
37. Ziad S, Nasreddine NAP, Be'dirian V, Simon Charbonneau VW, Isabelle Collin, Jeffrey L. Cummings HC. The Montreal Cognitive Assessment , MoCA : A Brief Screening. *J Am Geriatr Soc*. 2005;695–9.
38. Nolan JP, Soar J, Cariou A, Cronberg T, Moulaert VRM, Deakin CD, et al. European Resuscitation Council and European Society of Intensive Care Medicine 2015 guidelines for post-resuscitation care. *Intensive Care Med*. 2015;41(12):2039–56.
39. Boyce LW, Goossens PH, Moulaert VR, Pound G, van Heugten CM. Out-of-hospital cardiac arrest survivors need both cardiological and neurological rehabilitation! *Curr Opin Crit Care*. 2019;25(3):240–3.
40. Bellelli G, Morandi A, Davis DHJ, Mazzola P, Turco R, Gentile S, et al. Validation of the 4AT, a new instrument for rapid delirium screening: A study in 234 hospitalised older people. *Age Ageing*. 2014;43(4):496–502.
41. Hsueh I-P, Lin J-H, Jeng J-S, Hsieh C-L. Comparison of the psychometric characteristics of the functional independence measure, 5 item Barthel index, and 10 item Barthel index in patients with stroke. *J Neurol Neurosurg Psychiatry*. 2002;73(2):188–90.
42. www.fil.ion.ucl.ac.uk/spm/.
43. Whitfield-Gabrieli S, Nieto-Castanon A. Conn: A Functional Connectivity Toolbox for Correlated and Anticorrelated Brain Networks. *Brain Connect*. 2012;2(3):125–41.
44. Raichle ME. The Brain's Default Mode Network. *Annu Rev Neurosci*. 2015;(38):433–47.
45. Snaith RP. The Hospital Anxiety And Depression Scale. *Health Qual Life Outcomes*. 1983;1(6):29.
46. Creamer M, Bell R, Failla S. Psychometric properties of the Impact of Event Scale - Revised. *Behav Res Ther*. 2003;41(12):1489–96.
47. Bjelland I, Dahl AA HT. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *J Psychosom Res*. 2002;52:69–77.
48. Bryant, R. A., Harvey, A. G., Dang, S. T., & Sackville T. Assessing Acute Stress Disorder: Psychometric Properties of a Structured Clinical Interview. *Psychol Assess*. 1998;10(3):215–20.
49. American Psychiatric, Diagnosis and statistical manual of mental disorders, DSM-5. 5 th. American Psychiatric Association. Washington, DC; 2013.
50. Bryant RA, Friedman MJ, Spiegel D, Ursano R, Strain J. A review of acute stress disorder in DSM-5. *Depress Anxiety*. 2011;28(9):802–17.
51. Jensen CG, Hjordt L V., Stenbæk DS, Andersen E, Back SK, Lansner J, et al. Development and psychometric validation of the verbal affective memory test. *Memory*. 2016;24(9):1208–23.

- 1
- 2
- 3 52. Delis, D.C., Kaplan, E., & Kramer JH. Delis-Kaplan executive function system. In: The
- 4 Psychological Corporation. San Antonio, TX; 2001.
- 5
- 6 53. Somerville J, Tremont G, Stern RA, Somerville J, Tremont G, Stern RA. The Boston Qualitative
- 7 Scoring System as a Measure of Executive Functioning in Rey- Osterrieth Complex Figure
- 8 Performance The Boston Qualitative Scoring System as a Measure of Executive Functioning in Rey-
- 9 Osterrieth Complex Figure Performance *. 2010;3395(200010).
- 10
- 11 54. Wechsler DW. Adult Intelligence Scale. Third edit. San Antonio, TX: The Psychological
- 12 Corporation; 1997.
- 13
- 14 55. Lynge E, Sandegaard JL RMS. The Danish National Patient Register. Scand J Public Heal.
- 15 2011;39(7):30–3.
- 16
- 17 56. CB. P. The Danish Civil Registration System. Scand J Public Heal. 2011;39(7):22–5.
- 18
- 19 57. Wallach Kildemoes H, Toft Sørensen H, Hallas J. The Danish national prescription registry. Scand J
- 20 Public Health. 2011;39(7):38–41.
- 21
- 22 58. Jensen VM RA. Danish Education Registers. Scand J Public Heal. 2011;39(7):91–4.
- 23
- 24 59. Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public
- 25 Health. 2011;39(7):103–5.
- 26
- 27 60. Jensen CG, Hjordt L V., Stenbæk DS, Andersen E, Back SK, Lansner J, et al. Development and
- 28 psychometric validation of the verbal affective memory test. Memory. 2016;24(9):1208–23.
- 29
- 30 61. Wechsler, D., Coalson, D.L. and Raiford SE. WAIS-IV Technical and Interpretive Manual. San
- 31 Antonio, Texas: Pearson; 2008.
- 32
- 33 62. Weiss DS and Marmar CR. In TM WJ and K. The Impact of Event Scale-Revised. In: Assessing
- 34 psychological trauma and PTSD: A practioners handbook. New York: Guilford Press; 1997. p. 399–
- 35 411.
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The cognitive assessment		
	During hospitalisation	3-months follow up
Target cognitive domain	MoCA	Neuropsychological tests
Attention	Number sequence Letter list	D2 (visual attention) (Trail-making + stroop)
Visuospatial construction	Cube copying	Rey's figure
Episodic memory	Verbal memory test	VAMT-26
Working memory	Serial subtraction	Letter-number sequence
Executive functioning	Trail making B Clock drawing Abstraction	Trailmaking B D-KEFS colour-word interference
Psychomotor Processing speed	Trail making B	Trail making A and B
Language	Naming Repeating Word mobilization	
Orientation	Orientation	

MoCA: Montreal Cognitive Assessment, **D2:** D2 test of attention, **VAMT-26:** Danish Affective Verbal Memory Test-26 (VAMT-26), **D-KEFS:** Delis Kaplan Executive Function System

Table 1

Outcome domains, measurement instruments, time of measurement and quantity for the cardiac arrest survivors		
Outcome domains and measurement instruments	Time of measure	Type of quantity
Sociodemographic variables		
Age	T0	Continuous
Sex	T0	Binary
Marital status, type of occupation, employment status, living situation	T0	Categorical
Medical variables		
Known IHD, hypertension, previous MI, PCI or CABG, chronic heart failure, diabetes mellitus, COPD and chronic kidney disease	T0	Binary
Clinical variables related to the cardiac arrest		
Place of OHCA, aetiology of cardiac arrest, initial rhythm, TTM, medication during ICU stay, LVEF	T0	Categorical
Bystander witnessed cardiac arrest, bystander performed CPR, Use of AED, shockable rhythm, awake at arrival to hospital, TTM, intubated, medication during ICU, delirium at ICU	T0	Binary
Time to ROSC, intubation time, length of stay at ICU	T0	Continuous
Conscious state GCS	T0	Categorical
Neurological outcome CPC	T1	Categorical
Length of stay at hospital	T1	Continuous
Performance based variables		
Delirium score 4AT	T1	Categorical
Functional independence Barthel Index- 20	T1	Categorical
Cognitive status MoCA	T1	Binary
Brain activity while resting rsfMRI	T1	Continuous
Neuropsychological outcome VAMT-26, D- KEFS trail-taking, D-KEFS colour-word interference, D-KEFS design fluency, Rey's complex figure and Letter-number sequencing; sub-test of WAIS-IV	T2	Binary
Cortisol Awakening response	T1	Continuous
Patient-reported outcome measures		
POMS	T1	
HADS, IES-R, CSS	T1, T2	Continuous
B-IPQ, FSS, HeartQoL, SF-12, PSQI, CISS, BRIEF-A, ECR-R, AMCQ, CES-S, MTEQ, PTGQ, ACQ, NDEQ	T2	Continuous
Lifestyle changes, Health profile	T2	Categorical
Register based		
Depression, anxiety, dementia, chronic fatigue syndrome and heart failure, mortality and health care utilisation	T3	Continuous

T0: Pre-arrest, medical and clinical data, T1: During hospitalisation, T2: 3 months follow-up, T3: 1 year follow-up

ICU: Intensive Care Unit, **LVEF:** Left Ventricular Ejection Fraction, **OHCA:** Out-of-hospital Cardiac Arrest, **CPR:** Cardiopulmonary resuscitation, **AED:** Automated External Defibrillator, **ROSC:** Return of spontaneous circulation, **TTM:** Targeted Temperature Management, **IHD:** Ischemic Heart Disease, **MI:** Myocardial infarction, **PCI:** Percutaneous coronary Intervention, **CABG:** Coronary Artery Bypass Surgery, **COPD:** Chronic Obstructive Pulmonary Disease, **GCS:** Glasgow Coma Scale, **CPC:** Cerebral Performance Category, **MoCA:** Montreal Cognitive Assessment, **rsfMRI:** resting state functional magnetic resonance imaging, **VAMT-26:** Danish Affective Verbal Learning Test-26, **D- KEFS:** Delis-Kaplan Executive Function System, **POMS:** Profile of Mood States, **HADS:** Hospital Anxiety and Depression Scale, **IES-R:** Impact of Event- Revised, **CSS:** Crisis Support Scale, **B-IPQ:** Brief Illness Perception Scale, **FSS:** Fatigue Severity Scale, **SF-12:** 12-item short Form Survey, **PSQI:** Pittsburgh Sleep Quality Inventory, **CISS:** Coping Inventory for Stressful Situations, **BRIEF-A:** Behavior Rating Inventory of Executive Functions, adult version, **ECR-R:** Experience in close relationships, **AMCQ:** Autobiographical Memory Characteristics Questionnaire, **CES-S:** Centrality of Events – Short, **MTEQ:** Memory of Event Scale, **PTGQ:** Post Traumatic Growth Questionnaire, **ACQ:** Attribution, **NDEQ:** Near-death Experience Questionnaire,

Table 2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Outcome domains, measurement instruments and measurement time for the relatives		
Outcome domain	Measurement instruments	Time
Demographic variables and psychiatric medical history		T2
Health-related quality of life	SF-12	
Anxiety and Depression	HADS	
Distress caused by a traumatic event	IES-R	
Experience in close relationships	ECR-R	
Social support after a crisis	CSS	
Major depression	MDI	
The extent to which an event is viewed as being central to one's identity	CES-S	
Cognitive decline reported by informants (relatives or close friends)	IQ-CODE	

T2: 3 months follow-up

SF-12: 12-item Short Form Survey, HADS: Hospital Anxiety and Depression Scale, IES-R: Impact of Event- Revised, ECR-R: Experience in close relationships, CSS: The Crisis Support Scale, MDI: Major Depression Inventory, CES-S: Centrality of Event short, IQ-CODE: The Informant Questionnaire on Cognitive Decline in the Elderly.

Table 3




Figure 1: Flowchart of study assessment

T₀: Study inclusion, **T₁:** During hospitalisation, **T₂:** 3 months follow-up, **T₃:** 1-year follow-up




Figure 2

Direct patient-feed back

Supplementary material 1: Description of secondary outcomes

Sleep quality

The Pittsburgh Sleep Quality Inventory (**PSQI**) is a 19-item measure which assesses sleep quality and disturbances over the last months. The items generate a seven-component score each weighted equally on a 0-3 scale. The sum of these scores provides a global score. Higher scores indicate worse sleep quality. A cut-off score of >5 indicates poor sleep quality (64). The PSQI has demonstrated internal consistency reliability with Cronbach's α 0.83 (65).

Fatigue

Fatigue Severity Scale (**FSS**) is a nine-item questionnaire that measures experienced severity of fatigue symptoms in daily activities on a seven-point scale. A mean score is calculated (range 1–7) with higher scores reflecting greater fatigue. The FSS has shown construct validity with correlation coefficient of 0.68 with the visual analogue scale as external criterion and a Cronbach's α of 0.90 in stroke patients (66).

Executive functioning

Behaviour Rating Inventory of Executive Function (**BRIEF-A**) is a nine-item measure suitable for assessing adults executive functioning in everyday life. BRIEF-A measures different aspects of the executive functioning which are part of three overall clinical indices; *behavioral regulation*, *metacognition* and *general executive function*. Among others the BRIEF-A has been shown sensitive to assess executive function deficiencies in adults with a traumatic brain injury (67). The instrument has shown high internal consistency in clinical populations with a Cronbach's α ranging from 0.93 to 0.96 (68).

Health-related quality of life

The Medical Outcomes Study 12-item Short Form Health Survey (**SF-12**) is an abbreviated version of the SF-36 and a generic health-related quality of life measure. SF-12 measures eight domains of health on 2 domains, respectively physical health and mental health. The scores ranges from 0-10 with higher scores indicating a higher level of health-related quality of life (69). The instrument has been extensively validated in several populations and has shown good reliability when used in a stable coronary population (70).

Quality of life

The **Heart-QoL** is a 14-item heart disease-specific questionnaire that measures the Quality of life in cardiac patients. The scale is divided into a global, physical (10 items) and emotional (four items) component. Items are answered on a four-point Likert scale (range 0–3) with higher scores indicating better HRQoL. Heart-QoL has shown satisfactory internal consistency Cronbach's $\alpha > 0.90$ in Danish implantable cardioverter defibrillator recipients (71).

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Title page and abstract	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract page 3	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	page 5-7	
Objectives	3	State specific objectives, including any prespecified hypotheses	page 6-7	
Methods				
Study design	4	Present key elements of study design early in the paper	page 7-8	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	page 7-12	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	page 11-13	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	page 9-13	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	page 8-13	
Bias	9	Describe any efforts to address potential sources of bias	page 7-8	
Study size	10	Explain how the study size was arrived at	page 13	

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	page 13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	page 13
Results			N/A
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	

Continued on next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
----------------	----	--

Discussion

Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	----	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Cognitive impairment and psychopathology in Out-of-Hospital Cardiac Arrest survivors in Denmark. The REVIVAL cohort study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-038633.R1
Article Type:	Protocol
Date Submitted by the Author:	18-Aug-2020
Complete List of Authors:	Wagner, Mette; Copenhagen University Hospital, Rigshospitalet, Department of Cardiology Berg, Selina; Copenhagen University Hospital. Rigshospitalet , Department of Cardiology; University of Copenhagen, Department of Clinical Medicine Hassager, Christian; Copenhagen University Hospital, Rigshospitalet, Department of Cardiology ; University of Copenhagen, Department of Clinical Medicine Armand , Sophia; Copenhagen University Hospital, Rigshospitalet, Neurobiology Research Unit Møller, Jacob; Odense Universitetshospital, Department of Cardiology Ekholm, Ola; University of Southern Denmark, National Institute of Public Health Rasmussen, Trine; Gentofte University Hospital, Department of Cardiology Fisher, Patrick; Copenhagen University Hospital, Rigshospitalet, Neurobiology Research Unit and Center for Integrated Molecular Brain Imaging Knudsen, Gitte ; Copenhagen University Hospital, Rigshospitalet, Neurobiology Research Unit and of Center for Integrated Molecular Brain Imaging Stenbæk , Dea ; Copenhagen University Hospital, Rigshospitalet, Neurobiology Research Unit
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	MENTAL HEALTH, CARDIOLOGY, NEUROLOGY, Anxiety disorders < PSYCHIATRY, Depression & mood disorders < PSYCHIATRY, Magnetic resonance imaging < RADIOLOGY & IMAGING

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Cognitive impairment and psychopathology in Out-of-Hospital Cardiac Arrest survivors in Denmark.**
5 **The REVIVAL cohort study protocol**
6
7
8
9

10
11 Wagner, Mette Kirstine¹

12 Berg, Selina Kikkenborg^{1,2}

13 Hassager, Christian^{1,2}

14 Armand, Sophia³

15 Møller, Jacob Eifer⁴

16 Ekholm, Ola⁵

17 Rasmussen, Trine Bernholdt⁶

18 Fisher, Patrick MacDonald³

19 Knudsen, Gitte Moos³

20 Stenbæk, Dea Siggaard³
21
22
23
24
25
26
27
28
29
30
31

32 ¹Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

33 ²Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

34 ³Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

35 ⁴Department of Cardiology, Odense University Hospital, Odense, Denmark

36 ⁵National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.

37 ⁶Department of Cardiology, Herlev & Gentofte University Hospital, Hellerup, Denmark
38
39
40
41
42
43
44
45
46

47 **Correspondence to:**

48 Mette K. Wagner, RN, MSc, Department of Cardiology, Centre for Cardiac, Vascular, Pulmonary and
49 Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen,
50 Denmark

51 Email; mette.kirstine.wagner@regionh.dk

52 Telephone; +45 35453143
53
54
55

56 **Word count**

57 Abstract: 297 words

58 Main text: 3832 words
59
60

1
2
3
4
5
6 **Tables**
7

8 Table 1
9 **The cognitive assessment**
10
11

12 Table 2
13 **Outcome domains, measurement instruments, time of measurement and quantity for the cardiac**
14 **arrest survivors**
15
16

17 Table 3
18 **Outcome domains, measurement instruments and measurement time for the relatives**
19
20
21
22
23

24 **Figures**
25

26 Figure 1
27 **Flowchart of study assessment**
28
29

30 Figure 2
31 **Direct Patient Feed-back**
32
33
34

35 **Supplementary material 1:** Description of secondary outcomes
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

INTRODUCTION: Cognitive impairment and psychopathology caused by brain hypoxia and the traumatic impact of critical illness are common in cardiac arrest survivors and can lead to negative consequences of everyday life functioning, and further impact mental health in relatives. Most studies have dealt with the mere survival rate after cardiac arrest and not with long-term consequences to mental health in cardiac arrest survivors. Importantly, we face a gap in our knowledge about suitable screening tools in the early post-arrest phase for long-term risk prediction of mental health problems. This study aims to evaluate the efficacy of a novel screening procedure to predict risk of disabling cognitive impairment and psychopathology 3-months after cardiac arrest. Furthermore, the study aims to evaluate long-term prevalence of psychopathology in relatives.

METHODS AND ANALYSES: In this multicenter prospective cohort study, out-of-hospital cardiac arrest survivors and their relatives will be recruited. The post-arrest screening includes the Montreal Cognitive Assessment (MoCA), the Hospital Anxiety and Depression Scale (HADS), the Impact of Event Scale-Revised (IES-R) and the Acute Stress Disorder Interview (ASDI) and is conducted during hospitalisation. In a sub-sample of the patients, functional magnetic resonance imaging is done, and cortisol determination collected. At 3-months follow-up, the primary study outcomes for 200 survivors include the Danish Affective Verbal Learning Test-26 (VAMT-26), Delis-Kaplan Executive Function System tests (trail-making, colour-word interference, word and design fluency), Rey's Complex Figure and Letter-number sequencing sub-test of Wechsler Adult Intelligence Scale-IV, HADS and IES-R. For the relatives they include HADS and IES-R.

ETHICS AND DISSEMINATION: The study is approved by the local regional Research Ethics Committee (H-18046155) and the Danish Data Protection Agency (RH-2017-325, j.no.05961) and follows the latest version of the Declaration of Helsinki. The results will be published in peer-reviewed journals and may impact the follow-up of cardiac arrest survivors.

Article summary

Strength and limitations of this study

- A strength of the study is the prospective design and consistent follow-up with the use of standardised and validated measurement tools.
- A limitation of the study is the differential loss to follow-up which can introduce bias and challenge the internal validity of the study.
- A strength of the study is the multicenter approach. This will improve statistical power and generalisability of the results.
- A strength of the study is its potential to contribute to a better referral from cardiac care to targeted rehabilitation services.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

The global incidence of cardiac arrest with assumed primary cardiac cause is 55/100,000 inhabitants (1). In Europe approximately 275,000 people with all-rhythm cardiac arrests are treated by the Emergency Medical Systems (EMS) each year (2). Out-of-hospital cardiac arrest (OHCA) is a significant cause of global mortality (3). However, in recent years the survival rates have improved especially in developing countries due to advances in the chain of survival (1). At present the majority of published OHCA studies focus on the acute prehospital and intensive care treatment of OHCA sufferers. Far fewer studies have investigated the period from early recovery to long term return to everyday life. The existing literature on this period highlights two critical challenges for cardiac arrest survivors in the post-arrest recovery process, firstly diminished neurocognitive functions and secondly disabling emotional difficulties (4–9). In these survivors, long-term cognitive impairment and psychopathology constitute both a major personal and family burden, as well as a public health and economic concern (10–17).

Mild to moderate cognitive sequelae are reported in up to 50% of survivors (6,18). Transient or permanent memory loss, reduced visual–motor skills, attention deficit and executive impairment are the most dominant cognitive impairment found in this population (5,6,19,20). Importantly, impaired cognitive functioning at 3-months post-arrest has been found to correlate with worse physical and mental Health-related Quality of Life (HRQoL), and not being able to return to work around the first year after OHCA (21). Cardiac-induced cerebral hypoxia cause a diffuse injury that may damage the functional integrity of the brain (22) and cause cognitive impairment (23,24). Resting state functional magnetic resonance imaging (fMRI) is an informative imaging method that assays functional integrity and level of communication within the brain (3, 11). In a recent study, patients with increased within-network and decreased between-network functional connectivity in the acute phase after cardiac arrest survival had a favorable outcome (FO) one year later compared to patients with a non-favorable outcome (nFO) (13), suggesting higher functional integrity in patients with a FO. This increased within-network functional connectivity was also observed in a smaller study of cardiac arrest patients with good outcome at hospital discharge (14). To date, no reliable cognitive screening or

1
2
3
4
5 imaging method for use during the in-patient hospitalisation that can detect risk of long-term cognitive
6
7 impairment in cardiac arrest patients exist. A post-arrest screening model may contribute to prompt initiation
8
9 of relevant follow-up and targeted cognitive rehabilitation.
10

11
12
13 A cardiac arrest is a severe and traumatising life event and long-term post-arrest psychopathology is
14
15 prevalent (5,25–27). Processing near-death experiences, coping with prolonged preoccupation with somatic
16
17 symptoms and fear of a second cardiac arrest is a burden to many cardiac arrest patients (5,25). Up to 61% of
18
19 cardiac arrest patients experience anxiety, up to 45% depression and up to 27% post-traumatic stress disorder
20
21 (PTSD) (5). In particular, anxiety and depression have been found to negatively impact Health-related
22
23 Quality of Life (HRQoL) and physical health in patients up to several years after survival (28). Furthermore,
24
25 a cardiac arrest yields the highest prevalence of PTSD among cardiac disease categories (25), and PTSD is
26
27 reported to double the overall risk of mortality, recurrence of a new cardiac event, and causing long-term
28
29 diminished mental health and quality of life (8,29). Little is currently known about the role of acute
30
31 emotional reactions for developing long-term psychopathology in cardiac arrest survivors, but high acute
32
33 stress reactions in other patient populations appear to be associated with worse long-term outcomes (30–32).
34
35 Elucidating the role of acute emotional reactions may serve to support and advice the patients about future
36
37 challenges, and to initiate targeted psychological interventions.
38
39
40
41

42 Being the close relative of a cardiac arrest survivor can cause enduring psychological strains (33–35).
43
44 Research indicates that these psychological strains are caused by a burden of witnessing the cardiac arrest,
45
46 having to care for the patient and from the emotional stress of living with someone who is at risk of another
47
48 cardiac arrest (36). At 1-year post-arrest, 40% of the close relatives of patients with brain injury are still
49
50 experiencing a high impact of the cardiac event and display a more severe traumatic stress level than the
51
52 patient (Armand S. The acute traumatic stress response is associated with long-term post-traumatic stress in
53
54 cardiac arrest survivors and their close relatives, Unpublished, March, 2020) , and after 2 years these
55
56 caregivers show a higher level of trauma-related stress than that observed in the general population (37). As
57
58 a growing number of patients are surviving cardiac arrest it is crucial to focus more attention on
59
60

1
2
3
4 psychological challenges in relatives in the aftermath after surviving cardiac arrest.
5
6
7
8

9 The overall aim of the current study is therefore to evaluate and test a novel screening procedure during
10 hospitalisation for its ability to predict at-risk patients for disabling cognitive impairment and
11 psychopathology at 3-months. The incidence of psychopathology in close relatives 3-months post-arrest will
12 also be explored. Overall, we expect that the screening procedure will be able to identify at-risk patients for
13 disabling cognitive impairment and psychopathology at 3-months follow-up. In particular that:
14
15
16
17
18

19 Hypothesis 1: Lower level of cognitive impairment during hospitalisation (screening) is positively associated
20 with cognitive outcome at 3-month follow-up.
21
22
23

24 Hypothesis 2: The strength of discrete resting-state networks in the brain assessed with fMRI during
25 hospitalisation (screening) is positively associated with cognitive outcome at 3-months follow-up.
26
27
28

29 Hypothesis 3: Higher level of acute emotional reactions during hospitalisation (screening) is positively
30 associated with psychopathology outcome at 3-months follow-up.
31
32
33

34 Hypothesis 4: Higher level of cognitive impairment and emotional reactions during hospitalisation in patients
35 is positively associated with psychopathology outcomes in relatives at 3-months follow-up.
36
37
38
39
40
41
42

43 **METHODS AND ANALYSIS**

44 *Study design, setting and population*

45
46 The REVIVAL (REcovery after cardiac arrest surVIVAL) study is designed as a multicenter, prospective
47 cohort study in which first-time out-of-hospital cardiac arrest (OHCA) survivors are followed for up to 1
48 year after the event (flowchart presented in figure 1). The study settings are three highly specialized heart
49 centers at university hospitals in Denmark: Rigshospitalet and Herlev-Gentofte Hospital in the Capital
50 Region of Denmark and Odense University Hospital, in the Southern Region of Denmark. All cardiac arrest
51 patients will be approached for study participation and approximately 250 in-hospital patients (≥ 18 years of
52
53
54
55
56
57
58
59
60

1
2
3
4 age) with a first-time OHCA admission diagnosis will be recruited, starting January 1, 2018 and ending
5
6 December 31, 2021 Only patients with a presumed cardiac cause for their cardiac arrest, as defined by
7
8 Utstein template (38) will be included. Both cardiac arrests as primary and secondary diagnosis will be
9
10 included. Furthermore, the closest relatives will be identified and included during hospitalisation for a 3-
11
12 months follow-up. Patients are excluded if they have a serious not treatable other somatic or psychiatric
13
14 illness or previous cerebrovascular events or traumatic brain injury and those unable to speak and understand
15
16 Danish. The cognitive screening and neuropsychological testing require the patients to follow verbal
17
18 instructions and to see the tasks presented. Therefore, patients with solid hearing or visual impairments are
19
20 excluded. In a sub-study exploring resting state fMRI and stress reactivity, respectively 40 patients without
21
22 contraindications to MR will be included from Rigshospitalet. The REVIVAL study is described in
23
24 accordance with the current Strengthening the Reporting of Observational Studies in
25
26 Epidemiology (STROBE) statement (Guidelines for reporting observational studies) (39).
27
28
29
30
31

32 *Patient selection and recruitment*

33
34 All the patients and relatives are selected and recruited in the three Danish cardiology wards. OHCA
35
36 survivors transferred from the Intensive Care Units (ICU) to the ward will be included four to nine days after
37
38 termination of analgo-sedatives to ensure no residual sedation used during therapeutic hypothermia. The
39
40 survivors from the Coronary Care Units (CCU) who undergo percutaneous coronary intervention after a brief
41
42 cardiac arrest without ICU admission will be included after intervention in the cardiac catheterisation
43
44 laboratory (figure 1). This subgroup of cardiac arrest survivors will be included although they are awake or
45
46 only had a brief period of coma after admission to the hospital and presumably recover earlier to their
47
48 premorbid cognitive functioning than the critically ill patients. The patients and relatives at the included sites
49
50 follow the same protocol.
51
52
53
54

55
56 A trained cardiac nurse will collect most of the clinical data from the patients' charts. The same nurse will
57
58 approach eligible patients during hospital admission on the cardiology ward and invite them to participate in
59
60 the study. The patients will be assessed clinically and provided with oral as well as written information about

1
2
3
4 the study. The patients are given the opportunity to read and consider the study information leaflet carefully.
5
6 If the patients agree to participate, they will be asked to provide written informed consent in consultation
7
8 with their closest relative prior to inclusion. This is justified in ethical issues as some patients with cognitive
9
10 impairment may not feel empowered to refuse participation.
11
12
13
14

15 *Collection of data and measures*

16 Screening model during hospitalisation

17
18
19
20 A team of certified nurses with a background in cardiology will screen the patients. Administration and
21
22 interpretation of data will take place under supervision by a trained psychologist.
23
24

25 **Cognition:** The cognitive screening is conducted using the Danish version of the *Montreal Cognitive*
26
27 *Assessment tool* (MoCA), version 7.0 (40). The MoCA is a brief cognitive screening test designed to identify
28
29 mild cognitive impairment. The MoCA covers six cognitive domains: Attention, visuospatial construction,
30
31 executive functioning, memory, language and orientation (table 1), and is rated from 0-30. A cut-off ≥ 26 is
32
33 considered as normal cognitive function level. In the summary score a level of education ≤ 12 years is given
34
35 an extra point as education level has shown to decrease the overall score (40). The MoCA is suggested for
36
37 use in the post cardiac arrest settings (41), however, it remains to be evaluated in a Danish patient population
38
39 with possible hypoxic-ischaemic brain injury. The MoCA has shown high level of internal reliability with
40
41 Cronbach's $\alpha = 0.83$ in detection of mild cognitive impairment (40).
42
43
44
45
46

47 -Insert Table 1: **The cognitive assessment** about here-
48
49
50
51

52 **Mood and delirium:** As symptoms of delirium often are subtle but still can have an impact on cognition, the
53
54 cognitive screening is initiated with a rapid clinical assessment of delirium, using 4AT scale (42).
55
56 Furthermore, the mood state and functional independence of the patients is collected (table 2). If the study
57
58 nurse is in doubt regarding patients functioning, an informed nurse or relative is asked (43).
59
60

1
2
3
4
5
6
7 **Resting state fMRI:** Patients who meet inclusion criteria for MRI will undergo structural and functional
8 brain imaging on a 3 Tesla Siemens Prisma MRI scanner at Rigshospitalet. Trained personnel will perform
9 MRI scans; during transport and scanning, a trained nurse will monitor the patients. We will obtain high-
10 resolution structural T1- and T2-weighted images and T2*-weighted BOLD fMRI resting state scans (~10
11 minutes of resting state fMRI). During resting state fMRI, patients are asked to lie still with eyes closed and
12 let their mind wander freely. Resting state fMRI data will be processed using canonical brain imaging tools,
13 e.g. SPM (44) and Conn (45) to establish region-to-region connectivity estimates while accounting for
14 motion, physiological and other noise sources. Resting state networks will be defined based on *a priori*
15 connectivity networks descriptions (46).
16
17
18
19
20
21
22
23
24
25
26
27

28 **Psychopathology:** Self-rated symptoms of depression and anxiety and trauma reactions will be collected
29 using the Hospital Anxiety and Depression Scale (HADS-D and HADS-A) (47), and the Impact of event
30 Scale-revised (IES-R) (48). The Hospital Anxiety and Depression Scale (HADS) is a valid and internally
31 consistent 14 items instrument to measure anxiety and depression. Each item is scored from 0-3 with a
32 summary score between 0 and 21 for either anxiety or depression. Scores of 11 and above indicate the
33 probable presence of a mood disorder. HADS has shown a mean α of 0.83 and 0.82 for the HADS-A and
34 HADS-D, respectively (49). Impact of Event Scale - revised (IES-R) measures distress caused by a traumatic
35 event is a widely used measures to assess traumatic stress symptoms with a maximum score of 88. The IES-
36 R consist of 22-items measuring subjective distress caused by a traumatic event scored on a Likert scale from
37 0 (not at all) to 4 (extremely) and includes subscales for avoidance, intrusions and hyperarousal. The IES-R
38 has shown high internal consistency with coefficient alphas ranging from 0.84 to 0.85 for avoidance, 0.87 to
39 0.92 for intrusion, and 0.79 to 0.90 for hyperarousal (48).
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 **Acute Stress disorder:** The Acute Stress Disorder Structured interview (ASDI) is a 19-item clinical
56 interview which investigates the incidence and severity of acute stress responses operated as acute stress
57 disorder (ASD) in DSM-5 in the month following trauma exposure (50,51). Acute stress disorder is divided
58
59
60

1
2
3
4 into five symptom clusters: intrusive memories or revival, negative mood, dissociation, avoidance and
5
6 arousal. To meet the criteria for acute stress disorder, the patient must have experienced a traumatic event (in
7
8 this case a cardiac arrest) during the past month (criteria A) as well as the presence or deterioration of at least
9
10 nine symptoms independent of the associated category after the onset of episode (Criterion B), which should
11
12 occur within three days to one month (Criterion C) (52).
13
14
15
16

17 **Cortisol Awakening Response:** At the same day as the structured clinical interview (i.e. ASDI) is
18
19 performed, saliva samples for determination of the Cortisol Awakening Response (CAR) will be obtained
20
21 from eligible patients. Five samples are collected during awakening and three saliva samples will also be
22
23 collected during the day at 12 at 18 and at 23 o'clock. The total amount of saliva per patient is 16 ml. After
24
25 collecting the saliva, the samples will be stored and analysed at the Department of Clinical Biochemistry,
26
27 Rigshospitalet, Glostrup.
28
29

30 Sociodemographic variables and several clinical pre- and in-hospital data were obtained from electronic
31
32 medical records (see table 2).
33
34
35
36
37
38

39 -Insert Table 2: **Outcome domains, measurement instruments, time of measurement and quantity for**
40
41 **the cardiac arrest survivors** about here-
42
43
44
45
46
47

48 At 3-months follow-up

49
50 The patients included at Rigshospitalet and Herlev-Gentofte Hospital will undergo a detailed and individual
51
52 neuropsychological assessment at the Neurobiology Research Unit at Rigshospitalet, and patients included at
53
54 Odense University Hospital will be assessed with a similar test battery at the University of Southern
55
56 Denmark. The cognitive assessment of the patient's cognitive functions will be given, administered and
57
58
59
60

1
2
3
4 interpreted by a clinical and trained psychologist or psychology student under supervision. The patients and
5 their relatives will furthermore complete a package of self-reported questionnaires.
6
7
8

9 **The neuropsychological assessment:** The tests used are a carefully selected neuropsychological test battery
10 comprising the same subcomponents as for the MoCA; *attention, visuospatial construction, executive*
11 *functioning, memory, language and orientation*. The tests used are all validated in clinical settings for a
12 variety of populations and have shown good test-retest reliability. To address a source of bias, all tests are
13 conducted by a psychologist, who is kept blind of the clinical data as well as the results of the previous brief
14 cognitive screening. A detailed outline of the neuropsychological tasks includes: Danish Affective Verbal
15 Learning Test-26 (VAMT-26) (53) and Delis-Kaplan Executive Function System tests (D-KEFS) comprising
16 trail-making, colour-word interference, design fluency and word fluency (54) together with the Rey's
17 complex figure test (55) and Letter-number sequencing test from the Wechsler Adult Intelligence Scale-IV
18 (WAIS-IV) (56) (table 1).
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **Psychopathology in patients:** Furthermore, the patients will repeat the self-reported questionnaires identical
34 to the questionnaires completed during hospitalisation: HADS-D, HADS-A and IES-R.
35
36
37

38 **Psychopathology in relatives:** The relatives are also asked to complete the HADS-D, HADS-A and IES-R.
39 The questionnaires for both patients and their relatives are sent via e-mail two weeks before the 3-months
40 follow-up.
41
42
43
44
45

46 At 1-year follow-up

47
48 The 1-year follow-up is designed as register-based (table 2). To investigate whether baseline data are
49 associated with morbidity: depression, anxiety, dementia, chronic fatigue syndrome or heart failure and
50 with mortality and health care utilisation, the collected data will be linked with data from national
51 administrative registers; the Danish National Patient Register (57), the Danish Civil Registration System
52 (58), the Danish National Prescription Registry (59), the Danish education registers (60), and the Danish
53 registers on personal income and transfer payments (61).
54
55
56
57
58
59
60

1
2
3
4
5
6
7 *Primary and secondary study outcome measures*

8
9 *Primary outcome measures for patients*

10
11 The primary outcome is whether the patients present a favourable outcome (FO) or a non-favourable
12 outcome (nFO) at 3-month follow-up. To elucidate cognition and psychopathology separately, primary
13 outcomes will be established for each of these domains.
14
15
16

17
18 **Cognition:** As primary cognitive outcome the patients will be divided into two groups, FO and nFO, based
19 on their performance in the neuropsychological tasks. The subset with an nFO is defined as minimum 1.5
20 standard deviation (SD) under the norm or reference data (53,54,55,62) on minimum one test or 1 standard
21 deviation on two or more tests. The rest of the patients fall into the FO group.
22
23
24
25

26
27 **Psychopathology:** As primary psychopathology outcome the patients will be divided into two groups, FO
28 and nFO, based on their scores on the HADS and IES-R. The subset with an nFO is defined one or more
29 scores above cut-off for psychopathology on the HADS and IES-R: HADS-D and HADS-A >8 and IES-R
30 >24. The rest of the patients fall into the FO group.
31
32
33
34
35
36
37

38 *Secondary outcome measures for patients*

39
40 As secondary outcomes for patients are self-reported measures of sleep quality, fatigue, executive
41 functioning, and health-related quality of life at 3-months of follow-up (table 2). A detailed description of the
42 secondary outcomes is described in the supplementary material 1. Secondary outcomes for patients also
43 include register-based information of morbidity: depression, anxiety, dementia, chronic fatigue syndrome
44 or heart failure, mortality and healthcare utilisation at 1-year post-arrest (table 2).
45
46
47
48
49
50
51
52

53 *Primary outcome measures for relatives*

54
55 The primary outcomes for the relatives include HADS-D, HADS-A and IES-R (47,63) (table 3).
56
57
58
59
60

1
2
3
4 -Insert Table 3: **Outcome domains, measurement instruments and measurement time for the relatives**

5
6 about here-

7
8
9
10
11
12 *Secondary outcome measures for relatives*

13
14 Secondary outcome measures for relatives include self-reported health-related quality of life, experience of
15
16 cognitive changes in the patient after the cardiac arrest, social support, major depression, the quality in the
17
18 relationship with the cardiac arrest survivor, and the extent to which the cardiac arrest is viewed as being
19
20 central to one's identity (table 3).
21
22

23
24 Several exploratory outcomes will also be collected (figure 1).
25
26

27
28 *Data analysis plan*

29
30 The collected socio-demographic data will be presented as means \pm standard deviation (SD) or percentages,
31
32 respectively and group differences will be calculated by t-tests (continuous data) or χ^2 (categorical data).
33
34

35
36 Appropriate regression models will be used to examine the associations between screening performance
37
38 during hospitalisation and the primary and secondary study outcomes. In all model's relevant covariates e.g.
39
40 sex, age, comorbidity, time to return of spontaneous circulation, coma duration time, time at intensive care
41
42 unit, time of hospitalization, etc. will be included (table 2). A formal power calculation of sample size has
43
44 not been performed due to the several aims and potential analyses of this study. With no comparative patient
45
46 groups and only few small existing studies, we aim for a sample size of 200 cardiac arrest survivors at three
47
48 months follow-up for the primary outcome to be statistically and clinically significant.
49
50

51
52 *Patient and Public Involvement*

53
54 As a patient involvement method, two theme-based sessions involving *direct patient feedback* have been
55
56 carried out in the early pilot and design phase of the study. The aim of these sessions was to 1) identify
57
58 patient preferences regarding the cognitive screening procedure (figure 2), and 2) develop the research
59
60

1
2
3
4 priorities including implementation of possible changes based on the patient's feedback. Data derived from
5 the theme-based patient feed-back sessions provides the basis for the cognitive screening procedure in the
6
7 REVIVAL study. To ensure further patient involvement, we plan to engage the patients in the planning
8
9 phase of disseminating the results.
10
11
12
13
14

15 **DISCUSSION**

16
17 To the best of our knowledge, the present study will be the largest study evaluating and testing a novel
18 screening procedure for cognitive impairment and emotional reactions during hospitalisation in a population
19 of OHCA survivors. As the incidence of cardiac arrest survival is increasing, establishing a standardized
20 approach to screening in OHCA survivors will be critical in the future. Following the aims of the study and
21 to strengthen the standardization of the results, only patients with a presumed cardiac cause for their cardiac
22 arrest as defined by Utstein template will be included. Since a common single etiology of cardiac arrest is
23 respiratory failure, it could be considered to include this population in a future study. Although cognitive and
24 mental health outcomes in OHCA survivors may be comparable to other medical populations (7,64,65), the
25 study does not contain a comparative arm as it does not aim to investigate a specific intervention. Instead the
26 study seeks to investigate OHCA survivors after standard treatment in a naturalistic setting. Due to the nature
27 of the study and the vulnerable state of the patients, differential loss to follow-up is expected in the study. To
28 elucidate data missing not at random, we plan to conduct phone calls to non-responders at 3-months follow-
29 up regarding their withdrawal from the study. We expect that results from the REVIVAL study will inform
30 an early screening procedure of OHCA survivors in clinical settings as well as inform future targeted
31 rehabilitation in survivors who are likely to develop protracted cognitive impairment and psychopathology.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **ETHICS AND DISSEMINATION**

52
53 There is little to no discomfort for the patients and their relatives in this study. Due to the weakened
54 constitution of the patients, the neuropsychological test at 3-months post-arrest could be experienced as
55 taxing and can be divided into two days. The study complies with the Declaration of Helsinki and has been
56
57
58
59
60

1
2
3
4 approved by the Danish national committee on health research ethics (H-18046155) and the Danish Data
5 Protection Agency (RH-2017-325, I-Suite no: 05961). Patients and their relatives will receive oral and
6
7 written information about the study and inclusion will require obtained written consent for all participants
8
9 before enrolment. Results from this study will be disseminated at regional, national and international
10
11 conferences and in peer-reviewed journals.
12
13
14

17 **Authors' contributions**

18
19 Department of Cardiology, Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Copenhagen
20
21 University Hospital Rigshospitalet (MKW, SKB, and CH) and Neurobiology Research Unit, Rigshospitalet
22
23 (DSS, PMF and GMK) has full access to all the data in the study and takes responsibility for the integrity of
24
25 data. MKW, SKB, CH and DSS contributed to the study concept and design. MKW, SKB, CH, SA, JEM,
26
27 PMF, GMK and DSS contribute to the data acquisition. Analysis will be performed by MKW, SKB, CH, OE
28
29 and DSS, MKW and DSS drafted the manuscript with critical input from SKB, CH, SA, JEM, OE, TBR,
30
31 PMF and GMK. All authors approved the final version of the manuscript.
32
33
34
35

36 **Funding statement**

37
38 The REVIVAL study is funded by independent research grants from the following non-profit or
39
40 governmental agencies: The Research Foundation of Copenhagen University Hospital, Rigshospitalet,
41
42 Denmark (GNT 38-A2015 and GNT A5638), The Danish Knowledge Centre for Rehabilitation and
43
44 Palliative Care (REHPA) (GNT 34 177 058), The Helsefonden, Denmark (GNT 18-B-0235), The Danish
45
46 Heart Association (GNT 18-R124-A8454-22099, and from both The Research Committee and the Research
47
48 Committee in clinical nursing, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Denmark
49
50 (GNT Not Applicable).
51
52
53
54

55 **Competing interest statement**

56
57 On behalf of all authors, the corresponding author states that there are no conflicts of interest related to this
58
59 study. The funding sources have no role in the design and conduct of the study.
60

References

1. Porzer M, Mrazkova E, Homza M. et. al. Out-of-hospital cardiac arrest. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.* 2017;161(4):348–53.
2. Myat A, Song KJ, Rea T. Out-of-hospital cardiac arrest: current concepts. *Lancet.* 2018;391(10124):970–9.
3. Berdowski J, Berg RA, Tijssen JGP. et. al. Global incidences of out-of-hospital cardiac arrest and survival rates : Systematic review of 67 prospective studies. *Resuscitation.* 2010;81(11):1479–87.
4. Elliott VJ, Rodgers DL, Brett SJ. Systematic review of quality of life and other patient-centred outcomes after cardiac arrest survival. *Resuscitation.* 2011 Mar;82(3):247–56.
5. Green CR, Botha JA, Tiruvoipati R. Review Cognitive function , quality of life and mental health in survivors of out-of-hospital cardiac arrest : a review. *Anaesth Intensive Care.* 2015;43(5):568–77.
6. Moolaert VRMP, Verbunt JA, Heugten CM Van, Wade DT. Cognitive impairments in survivors of out-of-hospital cardiac arrest : A systematic review. *Resuscitation.* 2016;80(2009):297–305.
7. Cronberg T, Lilja G, Horn J, Kjaergaard J, Wise MP, Pellis T, et al. Neurologic Function and Health-Related Quality of Life in Patients Following Targeted Temperature Management at 33°C vs 36°C After Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. *JAMA Neurol.* 2015;72:634–41.
8. Wilder Schaaf KP, Artman LK, Peberdy MA. et al. Anxiety, depression, and PTSD following cardiac arrest: A systematic review of the literature. *Resuscitation.* 2013;84(7):873–7.
9. Fadayomi AB, Johnson-Akeju O. Neurocognitive Testing—Do We Lack in Expertise? *Crit Care Med.* 2019;47(6):e530–1.
10. Whitehead L, Perkins GD, Clarey a., Haywood KL. A systematic review of the outcomes reported in cardiac arrest clinical trials: THE need for a core outcome set. *Resuscitation.* 2015;88:150–7.
11. Perez C., Samudra N, Aiyagari V. Cognitive and Functional Consequence of Cardiac Arrest. *Curr Neurol Neurosci Rep.* 2016;16:70.
12. Sakusic A, O’Horo JC, Dziadzko M. et al. Potentially Modifiable Risk Factors for Long-Term Cognitive Impairment After Critical Illness: A Systematic Review. *Mayo Clin Proc.* 2018;93(1):68–82.
13. Davies SE, Rhys M, Voss S. et al. Psychological wellbeing in survivors of cardiac arrest, and its relationship to neurocognitive function. *Resuscitation* 111 (2017) 22–25
14. Wachelder EM, Moolaert VRMP, Van Heugten C. Life after survival : Long-term daily functioning and quality of life after an out-of-hospital cardiac arrest. *Resuscitation.* 2009;80:517–22.
15. Descatha A, Dumas F, Bougouin W. et. al. Work factors associated with return to work in out-of-hospital cardiac arrest survivors. *Resuscitation.* 2018;128:170–4.
16. Lilja G, Nielsen N, Bro-Jeppesen J. et al. Return to Work and Participation in Society After Out-of-Hospital Cardiac Arrest. *Circ Cardiovasc Qual Outcomes.* 2018;11(1):e003566.
17. Van Wijnen HGFM, Rasquin SMC, Van Heugten C. et al. The impact of cardiac arrest on the long-term wellbeing and caregiver burden of family caregivers: A prospective cohort study. *Clin Rehabil.*

- 2017;31(9):1267–75.
18. Cronberg T, Lilja G. Cognitive decline after cardiac arrest - It is more to the picture than hypoxic brain injury. *Resuscitation*. 2015;91(2015):A3–4.
 19. Van Heugten C, Gregório GW, Wade D. Evidence-based cognitive rehabilitation after acquired brain injury : A systematic review of content of treatment. *Neuropsychological Rehabilitation*. 2012;22(5):653-73.
 20. Mêdrzycka-Dabrowska WA, Czyz-Szybenbejl K, Kwiecień-Jagus K, Lewandowska K. Prediction of cognitive dysfunction after resuscitation-a systematic review. *Postep w Kardiol Interwencyjnej*. 2018;14(3):225–32.
 21. Moulaert VRM, Van Heugten C, Winkens B. et al. Early neurologically-focused follow-up after cardiac arrest improves quality of life at one year: A randomised controlled trial. *Int J Cardiol*. 2015;193.
 22. Barkhof F, Haller S, Rombouts SARB. Resting-State Functional MR Imaging: A New Window to the Brain. *Radiology*. 2014;272(1):29–49.
 23. Nolan JP, Soar J, Cariou A. et al. European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for Post-resuscitation Care 2015: Section 5 of the European Resuscitation Council Guidelines for Resuscitation 2015. *Resuscitation*. 2015;95:202–22.
 24. Hinduja A, Gupta H, Yang JD. et al. Hypoxic ischemic brain injury following in hospital cardiac arrest - Lessons from autopsy. *J Forensic Leg Med*. 2014;23(2014):84–6.
 25. Vilchinsky N, Ginzburg K, Fait K. et.al. Cardiac-disease-induced PTSD (CDI-PTSD): A systematic review. *Clin Psychol Rev*. 2017;55:92–106.
 26. Gamper G, Willeit M, Sterz F. et al. Life after death: Posttraumatic stress disorder in survivors of cardiac arrest - Prevalence, associated factors, and the influence of sedation and analgesia. *Crit Care Med*. 2004;32(2):378–83.
 27. Kamphuis HCM, De Leeuw JRJ, Derksen R. et al. A 12-month quality of life assessment of cardiac arrest survivors treated with or without an implantable cardioverter defibrillator. *Europace*. 2002;4(4):417–25.
 28. Moulaert V, Wachelder E, Verbunt J et al. Determinants of quality of life in survivors of cardiac arrest. *J Rehabil Med*. 2010;42(6):553–8.
 29. Edmondson D, Richardson S, Falzon L. et al. Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syndrome patients: A meta-analytic review. *PLoS One*. 2012;7(6).
 30. Visser E, Gosens T, Den Oudsten BL. et al. The course, prediction, and treatment of acute and posttraumatic stress in trauma patients. *J Trauma Acute Care Surg*. 2017;82(6):1158–83.
 31. Bryant, RA, Moulds ML, Guthrie RM. Acute Stress Disorder Scale: A Self-Report Measure of Acute Stress Disorder. *Psychol Assess*. 2000;12(1):61–8.
 32. Wessa, M, Rohleder, N, Kirschbaum C. et al. Altered cortisol awakening response in posttraumatic stress disorder. *Psychoneuroendocrinology*. 2006;31(2):209–15.
 33. Van Wijnen HGFM, Rasquin SMC, Van Heugten C. et al. The impact of cardiac arrest on the long-term wellbeing and caregiver burden of family caregivers: A prospective cohort study. *Clin Rehabil*. 2017;31(9):1267–75.

- 1
- 2
- 3
- 4
- 5 34. Zimmerli M, Tisljar K, Balestra GM. et al. Prevalence and risk factors for post-traumatic stress disorder in relatives of out-of-hospital cardiac arrest patients. *Resuscitation*. 2014;85(6):801-8.
- 6
- 7 35. Haywood K, Dainty KN. Life after cardiac arrest: The importance of engaging with the “forgotten patient.” *Resuscitation*. 2018;128:A1-2.
- 8
- 9
- 10 36. Moulaert V. Life after survival of a cardiac arrest: The brain is the heart of the matter. 2014.
- 11
- 12 37. Van't Wout Hofland J, Moulaert V, Van Heugten C. et al. Long-term quality of life of caregivers of cardiac arrest survivors and the impact of witnessing a cardiac event of a close relative. *Resuscitation*. 2018;128:198-203.
- 13
- 14
- 15 38. Nolan JP, Berg RA, Andersen LW. et al. Cardiac Arrest and Cardiopulmonary Resuscitation Outcome Reports: Update of the Utstein Resuscitation Registry Template for In-Hospital Cardiac Arrest: A Consensus Report From a Task Force of the International Liaison Committee on Resuscitation (American . *Circulation*. 2019;140(18):e746-57.
- 16
- 17 39. Vandembroucke JP, Von Elm E, Altman DG. et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. *PLoS Med*. 2007;4(10):1628-54.
- 18
- 19 40. Nasreddine ZS, Philips NA, Be'dirian V. et al. The Montreal Cognitive Assessment , MoCA : A Brief Screening. *J Am Geriatr Soc*. 2005;695-9.
- 20
- 21 41. Boyce LW, Goossens PH, Moulaert VR. et al. Out-of-hospital cardiac arrest survivors need both cardiological and neurological rehabilitation! *Curr Opin Crit Care*. 2019;25(3):240-3.
- 22
- 23 42. Bellelli G, Morandi A, Davis DHJ. et al. Validation of the 4AT, a new instrument for rapid delirium screening: A study in 234 hospitalised older people. *Age Ageing*. 2014;43(4):496-502.
- 24
- 25 43. Hsueh IP, Lin JH, Jeng JS. et al. Comparison of the psychometric characteristics of the functional independence measure, 5 item Barthel index, and 10 item Barthel index in patients with stroke. *J Neurol Neurosurg Psychiatry*. 2002;73(2):188-90.
- 26
- 27 44. www.fil.ion.ucl.ac.uk/spm/.
- 28
- 29 45. Whitfield-Gabrieli S, Nieto-Castanon A. Conn: A Functional Connectivity Toolbox for Correlated and Anticorrelated Brain Networks. *Brain Connect*. 2012;2(3):125-41.
- 30
- 31 46. Raichle ME. The Brain's Default Mode Network. *Annu Rev Neurosci*. 2015;(38):433-47.
- 32
- 33 47. Snaith RP. The Hospital Anxiety And Depression Scale. *Health Qual Life Outcomes*. 1983;1(6):29.
- 34
- 35 48. Creamer M, Bell R, Failla S. Psychometric properties of the Impact of Event Scale - Revised. *Behav Res Ther*. 2003;41(12):1489-96.
- 36
- 37 49. Bjelland I, Dahl AA, Haug TT. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *J Psychosom Res*. 2002;52:69-77.
- 38
- 39 50. Bryant RA., Harvey AG., Dang ST. et al. Assessing Acute Stress Disorder: Psychometric Properties of a Structured Clinical Interview. *Psychol Assess*. 1998;10(3):215-20.
- 40
- 41 51. American Psychiatric, *Diagnosis and statistical manual of mental disorders, DSM-5*. 5 th. American Psychiatric Association. Washington, DC; 2013.
- 42
- 43 52. Bryant RA, Friedman MJ, Spiegel D. et al. A review of acute stress disorder in DSM-5. *Depress Anxiety*. 2011;28(9):802-17.
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3
- 4
- 5 53. Jensen CG, Hjordt LV., Stenbæk DS. et al. Development and psychometric validation of the verbal
- 6 affective memory test. *Memory*. 2016;24(9):1208–23.
- 7
- 8 54. Delis DC., Kaplan, E, Kramer JH. Delis-Kaplan executive function system. In: *The Psychological*
- 9 *Corporation*. San Antonio, TX; 2001.
- 10
- 11 55. Somerville J, Tremont G, Stern RA. The Boston Qualitative Scoring System as a Measure of
- 12 Executive Functioning in Rey- Osterrieth Complex Figure Performance The Boston Qualitative
- 13 Scoring System as a Measure of Executive Functioning in Rey-Osterrieth Complex Figure
- 14 Performance *. 2010;3395(200010).
- 15
- 16 56. Wechsler DW. *Adult Intelligence Scale*. Third edit. San Antonio, TX: *The Psychological*
- 17 *Corporation*; 1997.
- 18
- 19 57. Lynge E, Sandegaard JL. The Danish National Patient Register. *Scand J Public Heal*. 2011;39(7):30–
- 20 3.
- 21
- 22 58. Pedersen CB. The Danish Civil Registration System. *Scand J Public Heal*. 2011;39(7):22–5.
- 23
- 24 59. Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescription registry. *Scand J Public*
- 25 *Health*. 2011;39(7):38–41.
- 26
- 27 60. Jensen VM RA. Danish Education Registers. *Scand J Public Heal*. 2011;39(7):91–4.
- 28
- 29 61. Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. *Scand J Public*
- 30 *Health*. 2011;39(7):103–5.
- 31
- 32 62. Wechsler, D., Coalson, D.L. and Raiford SE. *WAIS-IV Technical and Interpretive Manual*. San
- 33 *Antonio, Texas: Pearson*; 2008.
- 34
- 35 63. Weiss DS, Marmar CR. The Impact of Event Scale-Revised. In: *Assessing psychological trauma and*
- 36 *PTSD: A practioners handbook*. New York: Guilford Press; 1997. p. 399–411.
- 37
- 38 64. Orban JC, Truc M, Kerever S. et al. Comparison of presumed cardiac and respiratory causes of out-
- 39 of-hospital cardiac arrest. *Resuscitation*. 2018;129:24–8.
- 40
- 41 65. Jackson JC, Girard TD, Gordon SM. et al. Long-term cognitive and psychological outcomes in the
- 42 awakening and breathing controlled trial. *Am J Respir Crit Care Med*. 2010;182(2):183–91.
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Table 1: The cognitive assessment

The cognitive assessment		
	During hospitalisation	3-months follow up
Target cognitive domain	MoCA	Neuropsychological tests
Attention	Number sequence Letter list	D2 (visual attention) (Trail-making + stroop)
Visuospatial construction	Cube copying	Rey's figure
Episodic memory	Verbal memory test	VAMT-26
Working memory	Serial subtraction	Letter-number sequence
Executive functioning	Trail making B Clock drawing Abstraction	Trailmaking B D-KEFS colour-word interference
Psychomotor Processing speed	Trail making B	Trail making A and B
Language	Naming Repeating Word mobilization	
Orientation	Orientation	

Table 2: Outcome domains, measurement instruments, time of measurement and quantity for the cardiac arrest survivors

Outcome domains, measurement instruments, time of measurement and quantity for the cardiac arrest survivors		
Outcome domains and measurement instruments	Time of measure	Type of quantity
Sociodemographic variables		
Age	T0	Continuous
Sex	T0	Binary
Marital status, type of occupation, employment status, living situation	T0	Categorical
Medical variables		
Known IHD, hypertension, previous MI, PCI or CABG, chronic heart failure, diabetes mellitus, COPD and chronic kidney disease	T0	Binary
Clinical variables related to the cardiac arrest		
Place of OHCA, aetiology of cardiac arrest, initial rhythm, TTM, medication during ICU stay, LVEF	T0	Categorical
Bystander witnessed cardiac arrest, bystander performed CPR, Use of AED, shockable rhythm, awake at arrival to hospital, TTM, intubated, medication during ICU, delirium at ICU	T0	Binary
Time to ROSC, intubation time, length of stay at ICU	T0	Continuous
Conscious state GCS	T0	Categorical
Neurological outcome CPC	T1	Categorical
Length of stay at hospital	T1	Continuous
Performance based variables		
Delirium score 4AT	T1	Categorical
Functional independence Barthel Index- 20	T1	Categorical
Cognitive status MoCA	T1	Binary
Brain activity while resting rsfMRI	T1	Continuous
Neuropsychological outcome VAMT-26, D- KEFS trail-taking, D-KEFS colour-word interference, D-KEFS design fluency, Rey's complex figure and Letter-number sequencing: sub-test of WAIS-IV	T2	Binary
Cortisol Awakening response	T1	Continuous
Patient-reported outcome measures		
POMS	T1	
HADS, IES-R, CSS	T1, T2	Continuous
B-IPQ, FSS, HeartQoL, SF-12, PSQI, CISS, BRIEF-A, ECR-R, AMCQ, CES-S, MTEQ, PTGQ, ACQ, NDEQ	T2	Continuous
Lifestyle changes, Health profile	T2	Categorical
Register based		
Depression, anxiety, dementia, chronic fatigue syndrome and heart failure, mortality and health care utilisation	T3	Continuous

T0: Pre-arrest, medical and clinical data, T1: During hospitalisation, T2: 3 months follow-up, T3: 1 year follow-up

ICU: Intensive Care Unit, **LVEF:** Left Ventricular Ejection Fraction, **OHCA:** Out-of-hospital Cardiac Arrest, **CPR:** Cardiopulmonary resuscitation, **AED:** Automated External Defibrillator, **ROSC:** Return of spontaneous circulation, **TTM:** Targeted Temperature Management, **IHD:** Ischemic Heart Disease, **MI:** Myocardial infarction, **PCI:** Percutaneous coronary Intervention, **CABG:** Coronary Artery Bypass Surgery, **COPD:** Chronic Obstructive Pulmonary Disease, **GCS:** Glasgow Coma Scale, **CPC:** Cerebral Performance Category, **MoCA:** Montreal Cognitive Assessment, **rsfMRI:** resting state functional magnetic resonance imaging, **VAMT-26:** Danish Affective Verbal Learning Test-26, **D- KEFS:** Delis-Kaplan Executive Function System, **POMS:** Profile of Mood States, **HADS:** Hospital Anxiety and Depression Scale, **IES-R:** Impact of Event- Revised, **CSS:** Crisis Support Scale, **B-IPQ:** Brief Illness Perception Scale, **FSS:** Fatigue Severity Scale, **SF-12:** 12-item short Form Survey, **PSQI:** Pittsburgh Sleep Quality Inventory, **CISS:** Coping Inventory for Stressful Situations, **BRIEF-A:** Behavior Rating Inventory of Executive Functions, adult version, **ECR-R:** Experience in close relationships, **AMCQ:** Autobiographical Memory Characteristics Questionnaire, **CES-S:** Centrality of Events – Short, **MTEQ:** Memory of Event Scale, **PTGQ:** Post Traumatic Growth Questionnaire, **ACQ:** Attribution, **NDEQ:** Near-death Experience Questionnaire,

Table 3: Outcome domains, measurement instruments and measurement time for the relatives

Outcome domains, measurement instruments and measurement time for the relatives		
Outcome domain	Measurement instruments	Time
Demographic variables and psychiatric medical history		T2
Health-related quality of life	SF-12	
Anxiety and Depression	HADS	
Distress caused by a traumatic event	IES-R	
Experience in close relationships	ECR-R	
Social support after a crisis	CSS	
Major depression	MDI	
The extent to which an event is viewed as being central to one's identity	CES-S	
Cognitive decline reported by informants (relatives or close friends)	IQ-CODE	

T2: 3 months follow-up

SF-12: 12-item Short Form Survey, **HADS:** Hospital Anxiety and Depression Scale, **IES-R:** Impact of Event- Revised, **ECR-R:** Experience in close relationships, **CSS:** The Crisis Support Scale, **MDI:** Major Depression Inventory, **CES-S:** Centrality of Event short, **IQ-CODE:** The Informant Questionnaire on Cognitive Decline in the Elderly.




Figure 1: Flowchart of study assessment

T₀: Study inclusion, **T₁:** During hospitalisation, **T₂:** 3 months follow-up, **T₃:** 1-year follow-up

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2
Direct patient-feed back

279x82mm (96 x 96 DPI)

Supplementary material 1: Description of secondary outcomes

Sleep quality

The Pittsburgh Sleep Quality Inventory (**PSQI**) is a 19-item measure which assesses sleep quality and disturbances over the last months. The items generate a seven-component score each weighted equally on a 0-3 scale. The sum of these scores provides a global score. Higher scores indicate worse sleep quality. A cut-off score of >5 indicates poor sleep quality (64). The PSQI has demonstrated internal consistency reliability with Cronbach's α 0.83 (65).

Fatigue

Fatigue Severity Scale (**FSS**) is a nine-item questionnaire that measures experienced severity of fatigue symptoms in daily activities on a seven-point scale. A mean score is calculated (range 1–7) with higher scores reflecting greater fatigue. The FSS has shown construct validity with correlation coefficient of 0.68 with the visual analogue scale as external criterion and a Cronbach's α of 0.90 in stroke patients (66).

Executive functioning

Behaviour Rating Inventory of Executive Function (**BRIEF-A**) is a nine-item measure suitable for assessing adults executive functioning in everyday life. BRIEF-A measures different aspects of the executive functioning which are part of three overall clinical indices; *behavioral regulation*, *metacognition* and *general executive function*. Among others the BRIEF-A has been shown sensitive to assess executive function deficiencies in adults with a traumatic brain injury (67). The instrument has shown high internal consistency in clinical populations with a Cronbach's α ranging from 0.93 to 0.96 (68).

Health-related quality of life

The Medical Outcomes Study 12-item Short Form Health Survey (**SF-12**) is an abbreviated version of the SF-36 and a generic health-related quality of life measure. SF-12 measures eight domains of health on 2 domains, respectively physical health and mental health. The scores ranges from 0-10 with higher scores indicating a higher level of health-related quality of life (69). The instrument has been extensively validated in several populations and has shown good reliability when used in a stable coronary population (70).

Quality of life

The **Heart-QoL** is a 14-item heart disease-specific questionnaire that measures the Quality of life in cardiac patients. The scale is divided into a global, physical (10 items) and emotional (four items) component. Items are answered on a four-point Likert scale (range 0–3) with higher scores indicating better HRQoL. Heart-QoL has shown satisfactory internal consistency Cronbach's $\alpha > 0.90$ in Danish implantable cardioverter defibrillator recipients (71).

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	Title page and abstract	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract page 3	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	page 5-7	
Objectives	3	State specific objectives, including any prespecified hypotheses	page 6-7	
Methods				
Study design	4	Present key elements of study design early in the paper	page 7-8	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	page 7-12	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	page 11-13	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	page 9-13	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	page 8-13	
Bias	9	Describe any efforts to address potential sources of bias	page 7-8	
Study size	10	Explain how the study size was arrived at	page 13	

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	page 13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	page 13
Results			N/A
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	

Continued on next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

page 15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Cognitive impairment and psychopathology in Out-of-Hospital Cardiac Arrest survivors in Denmark. The REVIVAL cohort study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-038633.R2
Article Type:	Protocol
Date Submitted by the Author:	21-Aug-2020
Complete List of Authors:	Wagner, Mette; Copenhagen University Hospital, Rigshospitalet, Department of Cardiology Berg, Selina; Copenhagen University Hospital. Rigshospitalet , Department of Cardiology; University of Copenhagen, Department of Clinical Medicine Hassager, Christian; Copenhagen University Hospital, Rigshospitalet, Department of Cardiology ; University of Copenhagen, Department of Clinical Medicine Armand , Sophia; Copenhagen University Hospital, Rigshospitalet, Neurobiology Research Unit Møller, Jacob; Odense Universitetshospital, Department of Cardiology Ekholm, Ola; University of Southern Denmark, National Institute of Public Health Rasmussen, Trine; Gentofte University Hospital, Department of Cardiology Fisher, Patrick; Copenhagen University Hospital, Rigshospitalet, Neurobiology Research Unit and Center for Integrated Molecular Brain Imaging Knudsen, Gitte ; Copenhagen University Hospital, Rigshospitalet, Neurobiology Research Unit and of Center for Integrated Molecular Brain Imaging Stenbæk , Dea ; Copenhagen University Hospital, Rigshospitalet, Neurobiology Research Unit
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	MENTAL HEALTH, CARDIOLOGY, NEUROLOGY, Anxiety disorders < PSYCHIATRY, Depression & mood disorders < PSYCHIATRY, Magnetic resonance imaging < RADIOLOGY & IMAGING

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Cognitive impairment and psychopathology in Out-of-Hospital Cardiac Arrest survivors in Denmark.**
5 **The REVIVAL cohort study protocol**
6
7
8
9

10
11 Wagner, Mette Kirstine¹

12 Berg, Selina Kikkenborg^{1,2}

13 Hassager, Christian^{1,2}

14 Armand, Sophia³

15 Møller, Jacob Eifer⁴

16 Ekholm, Ola⁵

17 Rasmussen, Trine Bernholdt⁶

18 Fisher, Patrick MacDonald³

19 Knudsen, Gitte Moos³

20 Stenbæk, Dea Siggaard³

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

¹Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

²Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

³Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

⁴Department of Cardiology, Odense University Hospital, Odense, Denmark

⁵National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.

⁶Department of Cardiology, Herlev & Gentofte University Hospital, Hellerup, Denmark

Correspondence to:

Mette K. Wagner, RN, MSc, Department of Cardiology, Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Email; mette.kirstine.wagner@regionh.dk

Telephone; +45 35453143

Word count

Abstract: 297 words

Main text: 3832 words

1
2
3
4
5 **Tables**

6
7 Table 1
8 **The cognitive assessment**
9

10
11 Table 2
12 **Outcome domains, measurement instruments, time of measurement and quantity for the cardiac**
13 **arrest survivors**
14

15
16 Table 3
17 **Outcome domains, measurement instruments and measurement time for the relatives**
18
19

20
21
22
23 **Figures**

24
25 Figure 1
26 **Flowchart of study assessment**
27

28 Figure 2
29 **Direct Patient Feed-back**
30
31

32
33
34 **Supplementary material 1:** Description of secondary outcomes
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

INTRODUCTION: Cognitive impairment and psychopathology caused by brain hypoxia and the traumatic impact of critical illness are common in cardiac arrest survivors and can lead to negative consequences of everyday life functioning, and further impact mental health in relatives. Most studies have dealt with the mere survival rate after cardiac arrest and not with long-term consequences to mental health in cardiac arrest survivors. Importantly, we face a gap in our knowledge about suitable screening tools in the early post-arrest phase for long-term risk prediction of mental health problems. This study aims to evaluate the efficacy of a novel screening procedure to predict risk of disabling cognitive impairment and psychopathology 3-months after cardiac arrest. Furthermore, the study aims to evaluate long-term prevalence of psychopathology in relatives.

METHODS AND ANALYSES: In this multicenter prospective cohort study, out-of-hospital cardiac arrest survivors and their relatives will be recruited. The post-arrest screening includes the Montreal Cognitive Assessment (MoCA), the Hospital Anxiety and Depression Scale (HADS), the Impact of Event Scale-Revised (IES-R) and the Acute Stress Disorder Interview (ASDI) and is conducted during hospitalisation. In a sub-sample of the patients, functional magnetic resonance imaging is done, and cortisol determination collected. At 3-months follow-up, the primary study outcomes for 200 survivors include the Danish Affective Verbal Learning Test-26 (VAMT-26), Delis-Kaplan Executive Function System tests (trail-making, colour-word interference, word and design fluency), Rey's Complex Figure and Letter-number sequencing sub-test of Wechsler Adult Intelligence Scale-IV, HADS and IES-R. For the relatives they include HADS and IES-R.

ETHICS AND DISSEMINATION: The study is approved by the local regional Research Ethics Committee (H-18046155) and the Danish Data Protection Agency (RH-2017-325, j.no.05961) and follows the latest version of the Declaration of Helsinki. The results will be published in peer-reviewed journals and may impact the follow-up of cardiac arrest survivors.

Article summary

Strength and limitations of this study

- A strength of the study is the prospective design and consistent follow-up with the use of standardised and validated measurement tools.
- A limitation of the study is the differential loss to follow-up which can introduce bias and challenge the internal validity of the study.
- A strength of the study is the multicenter approach. This will improve statistical power and generalisability of the results.
- A strength of the study is its potential to contribute to a better referral from cardiac care to targeted rehabilitation services.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

The global incidence of cardiac arrest with assumed primary cardiac cause is 55/100,000 inhabitants (1). In Europe approximately 275,000 people with all-rhythm cardiac arrests are treated by the Emergency Medical Systems (EMS) each year (2). Out-of-hospital cardiac arrest (OHCA) is a significant cause of global mortality (3). However, in recent years the survival rates have improved especially in developing countries due to advances in the chain of survival (1). At present the majority of published OHCA studies focus on the acute prehospital and intensive care treatment of OHCA sufferers. Far fewer studies have investigated the period from early recovery to long term return to everyday life. The existing literature on this period highlights two critical challenges for cardiac arrest survivors in the post-arrest recovery process, firstly diminished neurocognitive functions and secondly disabling emotional difficulties (4–7). In these survivors, long-term cognitive impairment and psychopathology constitute both a major personal and family burden, as well as a public health and economic concern (8–15).

Mild to moderate cognitive sequelae are reported in up to 50% of survivors (6,16). Transient or permanent memory loss, reduced visual–motor skills, attention deficit and executive impairment are the most dominant cognitive impairment found in this population (5,6,17,18). Importantly, impaired cognitive functioning at 3-months post-arrest has been found to correlate with worse physical and mental Health-related Quality of Life (HRQoL), and not being able to return to work around the first year after OHCA (19). Cardiac-induced cerebral hypoxia cause a diffuse injury that may damage the functional integrity of the brain (20) and cause cognitive impairment (21,22). Resting state functional magnetic resonance imaging (fMRI) is an informative imaging method that assays functional integrity and level of communication within the brain (23). In a recent study, patients with increased within-network and decreased between-network functional connectivity in the acute phase after cardiac arrest survival had a favorable outcome (FO) one year later compared to patients with a non-favorable outcome (nFO) (13), suggesting higher functional integrity in patients with a FO. This increased within-network functional connectivity was also observed in a smaller study of cardiac arrest patients with good outcome at hospital discharge (14). To date, no reliable cognitive screening or imaging method for use during the in-patient hospitalisation that can detect risk of long-term cognitive impairment in

1
2
3 cardiac arrest patients exist. A post-arrest screening model may contribute to prompt initiation of relevant
4
5 follow-up and targeted cognitive rehabilitation.
6
7
8

9 A cardiac arrest is a severe and traumatising life event and long-term post-arrest psychopathology is
10 prevalent (5,24–26). Processing near-death experiences, coping with prolonged preoccupation with somatic
11 symptoms and fear of a second cardiac arrest is a burden to many cardiac arrest patients (5,24). Up to 61% of
12 cardiac arrest patients experience anxiety, up to 45% depression and up to 27% post-traumatic stress disorder
13 (PTSD) (5). In particular, anxiety and depression have been found to negatively impact Health-related
14 Quality of Life (HRQoL) and physical health in patients up to several years after survival (27). Furthermore,
15 a cardiac arrest yields the highest prevalence of PTSD among cardiac disease categories (24), and PTSD is
16 reported to double the overall risk of mortality, recurrence of a new cardiac event, and causing long-term
17 diminished mental health and quality of life (28,29). Little is currently known about the role of acute
18 emotional reactions for developing long-term psychopathology in cardiac arrest survivors, but high acute
19 stress reactions in other patient populations appear to be associated with worse long-term outcomes (30–32).
20 Elucidating the role of acute emotional reactions may serve to support and advice the patients about future
21 challenges, and to initiate targeted psychological interventions.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 Being the close relative of a cardiac arrest survivor can cause enduring psychological strains (33–35).
40 Research indicates that these psychological strains are caused by a burden of witnessing the cardiac arrest,
41 having to care for the patient and from the emotional stress of living with someone who is at risk of another
42 cardiac arrest (36). At 1-year post-arrest, 40% of the close relatives of patients with brain injury are still
43 experiencing a high impact of the cardiac event and display a more severe traumatic stress level than the
44 patient (Armand S. The acute traumatic stress response is associated with long-term post-traumatic stress in
45 cardiac arrest survivors and their close relatives, Unpublished, March, 2020) , and after 2 years these
46 caregivers show a higher level of trauma-related stress than that observed in the general population (37). As
47 a growing number of patients are surviving cardiac arrest it is crucial to focus more attention on
48 psychological challenges in relatives in the aftermath after surviving cardiac arrest.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The overall aim of the current study is therefore to evaluate and test a novel screening procedure during
4 hospitalisation for its ability to predict at-risk patients for disabling cognitive impairment and
5 psychopathology at 3-months. The incidence of psychopathology in close relatives 3-months post-arrest will
6 also be explored. Overall, we expect that the screening procedure will be able to identify at-risk patients for
7 disabling cognitive impairment and psychopathology at 3-months follow-up. In particular that:
8
9
10
11
12

13
14 Hypothesis 1: Lower level of cognitive impairment during hospitalisation (screening) is positively associated
15 with cognitive outcome at 3-month follow-up.
16
17

18
19 Hypothesis 2: The strength of discrete resting-state networks in the brain assessed with fMRI during
20 hospitalisation (screening) is positively associated with cognitive outcome at 3-months follow-up.
21
22

23
24 Hypothesis 3: Higher level of acute emotional reactions during hospitalisation (screening) is positively
25 associated with psychopathology outcome at 3-months follow-up.
26
27

28
29 Hypothesis 4: Higher level of cognitive impairment and emotional reactions during hospitalisation in patients
30 is positively associated with psychopathology outcomes in relatives at 3-months follow-up.
31
32
33
34
35
36

37 **METHODS AND ANALYSIS**

38 *Study design, setting and population*

39
40
41 The REVIVAL (REcovery after cardiac arrest surVIVAL) study is designed as a multicenter, prospective
42 cohort study in which first-time out-of-hospital cardiac arrest (OHCA) survivors are followed for up to 1
43 year after the event (flowchart presented in figure 1). The study settings are three highly specialized heart
44 centers at university hospitals in Denmark: Rigshospitalet and Herlev-Gentofte Hospital in the Capital
45 Region of Denmark and Odense University Hospital, in the Southern Region of Denmark. All cardiac arrest
46 patients will be approached for study participation and approximately 250 in-hospital patients (≥ 18 years of
47 age) with a first-time OHCA admission diagnosis will be recruited, starting January 1, 2018 and ending
48 December 31, 2021 Only patients with a presumed cardiac cause for their cardiac arrest, as defined by
49 Utstein template will be included (38). Both cardiac arrests as primary and secondary diagnosis will be
50
51
52
53
54
55
56
57
58
59
60

1
2
3 included. Furthermore, the closest relatives will be identified and included during hospitalisation for a 3-
4 months follow-up. Patients are excluded if they have a serious not treatable other somatic or psychiatric
5 illness or previous cerebrovascular events or traumatic brain injury and those unable to speak and understand
6 Danish. The cognitive screening and neuropsychological testing require the patients to follow verbal
7 instructions and to see the tasks presented. Therefore, patients with solid hearing or visual impairments are
8 excluded. In a sub-study exploring resting state fMRI and stress reactivity, respectively 40 patients without
9 contraindications to MR will be included from Rigshospitalet. The REVIVAL study is described in
10 accordance with the current Strengthening the Reporting of Observational Studies in
11 Epidemiology (STROBE) statement (Guidelines for reporting observational studies) (39).
12
13
14
15
16
17
18
19
20
21
22
23

24 *Patient selection and recruitment*

25
26 All the patients and relatives are selected and recruited in the three Danish cardiology wards. OHCA
27 survivors transferred from the Intensive Care Units (ICU) to the ward will be included four to nine days after
28 termination of analgo-sedatives to ensure no residual sedation used during therapeutic hypothermia. The
29 survivors from the Coronary Care Units (CCU) who undergo percutaneous coronary intervention after a brief
30 cardiac arrest without ICU admission will be included after intervention in the cardiac catheterisation
31 laboratory (figure 1). This subgroup of cardiac arrest survivors will be included although they are awake or
32 only had a brief period of coma after admission to the hospital and presumably recover earlier to their
33 premorbid cognitive functioning than the critically ill patients. The patients and relatives at the included sites
34 follow the same protocol.
35
36
37
38
39
40
41
42
43
44
45
46
47

48 A trained cardiac nurse will collect most of the clinical data from the patients' charts. The same nurse will
49 approach eligible patients during hospital admission on the cardiology ward and invite them to participate in
50 the study. The patients will be assessed clinically and provided with oral as well as written information about
51 the study. The patients are given the opportunity to read and consider the study information leaflet carefully.
52 If the patients agree to participate, they will be asked to provide written informed consent in consultation
53 with their closest relative prior to inclusion. This is justified in ethical issues as some patients with cognitive
54
55
56
57
58
59
60

1
2
3 impairment may not feel empowered to refuse participation.
4
5
6

7
8 *Collection of data and measures*
9

10 Screening model during hospitalisation
11

12 A team of certified nurses with a background in cardiology will screen the patients. Administration and
13 interpretation of data will take place under supervision by a trained psychologist (40).
14
15

16
17 **Cognition:** The cognitive screening is conducted using the Danish version of the *Montreal Cognitive*
18 *Assessment tool* (MoCA), version 7.0 (41). The MoCA is a brief cognitive screening test designed to identify
19 mild cognitive impairment. The MoCA covers six cognitive domains: Attention, visuospatial construction,
20 executive functioning, memory, language and orientation (table 1), and is rated from 0-30. A cut-off ≥ 26 is
21 considered as normal cognitive function level. In the summary score a level of education ≤ 12 years is given
22 an extra point as education level has shown to decrease the overall score (41). The MoCA is suggested for
23 use in the post cardiac arrest settings (21,42), however, it remains to be evaluated in a Danish patient
24 population with possible hypoxic-ischaemic brain injury. The MoCA has shown high level of internal
25 reliability with Cronbach's $\alpha = 0.83$ in detection of mild cognitive impairment (41).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

-Insert Table 1: **The cognitive assessment** about here-

Mood and delirium: As symptoms of delirium often are subtle but still can have an impact on cognition, the
cognitive screening is initiated with a rapid clinical assessment of delirium, using 4AT scale (43).

Furthermore, the mood state and functional independence of the patients is collected (table 2). If the study
nurse is in doubt regarding patients functioning, an informed nurse or relative is asked (44).

Resting state fMRI: Patients who meet inclusion criteria for MRI will undergo structural and functional
brain imaging on a 3 Tesla Siemens Prisma MRI scanner at Rigshospitalet. Trained personnel will perform
MRI scans; during transport and scanning, a trained nurse will monitor the patients. We will obtain high-

1
2
3 resolution structural T1- and T2-weighted images and T2*-weighted BOLD fMRI resting state scans (~10
4 minutes of resting state fMRI). During resting state fMRI, patients are asked to lie still with eyes closed and
5 let their mind wander freely. Resting state fMRI data will be processed using canonical brain imaging tools,
6 e.g. SPM (45) and Conn (23) to establish region-to-region connectivity estimates while accounting for
7 motion, physiological and other noise sources. Resting state networks will be defined based on *a priori*
8 connectivity networks descriptions (46).
9
10
11
12
13
14

15
16
17
18 **Psychopathology:** Self-rated symptoms of depression and anxiety and trauma reactions will be collected
19 using the Hospital Anxiety and Depression Scale (HADS-D and HADS-A) (47), and the Impact of event
20 Scale-revised (IES-R) (48). The Hospital Anxiety and Depression Scale (HADS) is a valid and internally
21 consistent 14 items instrument to measure anxiety and depression. Each item is scored from 0-3 with a
22 summary score between 0 and 21 for either anxiety or depression. Scores of 11 and above indicate the
23 probable presence of a mood disorder. HADS has shown a mean α of 0.83 and 0.82 for the HADS-A and
24 HADS-D, respectively (49). Impact of Event Scale - revised (IES-R) measures distress caused by a traumatic
25 event is a widely used measures to assess traumatic stress symptoms with a maximum score of 88. The IES-
26 R consist of 22-items measuring subjective distress caused by a traumatic event scored on a Likert scale from
27 0 (not at all) to 4 (extremely) and includes subscales for avoidance, intrusions and hyperarousal. The IES-R
28 has shown high internal consistency with coefficient alphas ranging from 0.84 to 0.85 for avoidance, 0.87 to
29 0.92 for intrusion, and 0.79 to 0.90 for hyperarousal (48).
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Acute Stress disorder:** The Acute Stress Disorder Structured interview (ASDI) is a 19-item clinical
46 interview which investigates the incidence and severity of acute stress responses operated as acute stress
47 disorder (ASD) in DSM-5 in the month following trauma exposure (50,51). Acute stress disorder is divided
48 into five symptom clusters: intrusive memories or revival, negative mood, dissociation, avoidance and
49 arousal. To meet the criteria for acute stress disorder, the patient must have experienced a traumatic event (in
50 this case a cardiac arrest) during the past month (criteria A) as well as the presence or deterioration of at least
51 nine symptoms independent of the associated category after the onset of episode (Criterion B), which should
52 occur within three days to one month (Criterion C) (52).
53
54
55
56
57
58
59
60

1
2
3
4
5 **Cortisol Awakening Response:** At the same day as the structured clinical interview (i.e. ASDI) is
6 performed, saliva samples for determination of the Cortisol Awakening Response (CAR) will be obtained
7 from eligible patients. Five samples are collected during awakening and three saliva samples will also be
8 collected during the day at 12 at 18 and at 23 o'clock. The total amount of saliva per patient is 16 ml. After
9 collecting the saliva, the samples will be stored and analysed at the Department of Clinical Biochemistry,
10 Rigshospitalet, Glostrup.
11
12
13
14
15
16
17

18 Sociodemographic variables and several clinical pre- and in-hospital data were obtained from electronic
19 medical records (see table 2).
20
21
22
23
24
25

26 -Insert Table 2: **Outcome domains, measurement instruments, time of measurement and quantity for**
27 **the cardiac arrest survivors** about here-
28
29
30
31
32
33
34
35

36 At 3-months follow-up

37
38 The patients included at Rigshospitalet and Herlev-Gentofte Hospital will undergo a detailed and individual
39 neuropsychological assessment at the Neurobiology Research Unit at Rigshospitalet, and patients included at
40 Odense University Hospital will be assessed with a similar test battery at the University of Southern
41 Denmark. The cognitive assessment of the patient's cognitive functions will be given, administered and
42 interpreted by a clinical and trained psychologist or psychology student under supervision. The patients and
43 their relatives will furthermore complete a package of self-reported questionnaires.
44
45
46
47
48
49
50

51 **The neuropsychological assessment:** The tests used are a carefully selected neuropsychological test battery
52 comprising the same subcomponents as for the MoCA; *attention, visuospatial construction, executive*
53 *functioning, memory, language and orientation*. The tests used are all validated in clinical settings for a
54 variety of populations and have shown good test-retest reliability. To address a source of bias, all tests are
55 conducted by a psychologist, who is kept blind of the clinical data as well as the results of the previous brief
56
57
58
59
60

1
2
3 cognitive screening. A detailed outline of the neuropsychological tasks includes: Danish Affective Verbal
4 Learning Test-26 (VAMT-26) (53) and Delis-Kaplan Executive Function System tests (D-KEFS) comprising
5 trail-making, colour-word interference, design fluency and word fluency (54) together with the Rey's
6 complex figure test (55) and Letter-number sequencing test from the Wechsler Adult Intelligence Scale-IV
7 (WAIS-IV) (56) (table 1).
8
9
10
11
12

13
14
15 **Psychopathology in patients:** Furthermore, the patients will repeat the self-reported questionnaires identical
16 to the questionnaires completed during hospitalisation: HADS-D, HADS-A and IES-R.
17

18
19
20 **Psychopathology in relatives:** The relatives are also asked to complete the HADS-D, HADS-A and IES-R.
21 The questionnaires for both patients and their relatives are sent via e-mail two weeks before the 3-months
22 follow-up.
23
24
25
26
27

28 29 At 1-year follow-up

30
31 The 1-year follow-up is designed as register-based (table 2). To investigate whether baseline data are
32 associated with morbidity: depression, anxiety, dementia, chronic fatigue syndrome or heart failure and
33 with mortality and health care utilisation, the collected data will be linked with data from national
34 administrative registers; the Danish National Patient Register (57), the Danish Civil Registration System
35 (58), the Danish National Prescription Registry (59), the Danish education registers (60), and the Danish
36 registers on personal income and transfer payments (61).
37
38
39
40
41
42
43
44
45

46 *Primary and secondary study outcome measures*

47 *Primary outcome measures for patients*

48
49 The primary outcome is whether the patients present a favourable outcome (FO) or a non-favourable
50 outcome (nFO) at 3-month follow-up. To elucidate cognition and psychopathology separately, primary
51 outcomes will be established for each of these domains.
52
53
54
55
56

57
58 **Cognition:** As primary cognitive outcome the patients will be divided into two groups, FO and nFO, based
59 on their performance in the neuropsychological tasks. The subset with an nFO is defined as minimum 1.5
60

1
2
3 standard deviation (SD) under the norm or reference data (53–55,62) on minimum one test or 1 standard
4 deviation on two or more tests. The rest of the patients fall into the FO group.
5
6
7

8 **Psychopathology:** As primary psychopathology outcome the patients will be divided into two groups, FO
9 and nFO, based on their scores on the HADS and IES-R. The subset with an nFO is defined one or more
10 scores above cut-off for psychopathology on the HADS and IES-R: HADS-D and HADS-A >8 and IES-R
11 >24. The rest of the patients fall into the FO group.
12
13
14
15
16
17

18 *Secondary outcome measures for patients*

19
20 As secondary outcomes for patients are self-reported measures of sleep quality, fatigue, executive
21 functioning, and health-related quality of life at 3-months of follow-up (table 2). A detailed description of the
22 secondary outcomes is described in the supplementary material 1. Secondary outcomes for patients also
23 include register-based information of morbidity: depression, anxiety, dementia, chronic fatigue syndrome
24 or heart failure, mortality and healthcare utilisation at 1-year post-arrest (table 2).
25
26
27
28
29
30
31
32

33 *Primary outcome measures for relatives*

34
35 The primary outcomes for the relatives include HADS-D, HADS-A and IES-R (47,63) (table 3).
36
37
38
39
40

41 -Insert Table 3: **Outcome domains, measurement instruments and measurement time for the relatives**
42 about here-
43
44
45
46
47
48

49 *Secondary outcome measures for relatives*

50
51 Secondary outcome measures for relatives include self-reported health-related quality of life, experience of
52 cognitive changes in the patient after the cardiac arrest, social support, major depression, the quality in the
53 relationship with the cardiac arrest survivor, and the extent to which the cardiac arrest is viewed as being
54 central to one's identity (table 3).
55
56
57
58
59
60

1
2
3 Several exploratory outcomes will also be collected (figure 1).
4
5
6

7 8 *Data analysis plan* 9

10 The collected socio-demographic data will be presented as means \pm standard deviation (SD) or percentages,
11 respectively and group differences will be calculated by t-tests (continuous data) or χ^2 (categorical data).
12

13
14 Appropriate regression models will be used to examine the associations between screening performance
15 during hospitalisation and the primary and secondary study outcomes. In all model's relevant covariates e.g.
16 sex, age, comorbidity, time to return of spontaneous circulation, coma duration time, time at intensive care
17 unit, time of hospitalization, etc. will be included (table 2). A formal power calculation of sample size has
18 not been performed due to the several aims and potential analyses of this study. With no comparative patient
19 groups and only few small existing studies, we aim for a sample size of 200 cardiac arrest survivors at three
20 months follow-up for the primary outcome to be statistically and clinically significant.
21
22
23
24
25
26
27
28
29

30 31 *Patient and Public Involvement* 32

33 As a patient involvement method, two theme-based sessions involving *direct patient feedback* have been
34 carried out in the early pilot and design phase of the study. The aim of these sessions was to 1) identify
35 patient preferences regarding the cognitive screening procedure (figure 2), and 2) develop the research
36 priorities including implementation of possible changes based on the patient's feedback. Data derived from
37 the theme-based patient feed-back sessions provides the basis for the cognitive screening procedure in the
38 REVIVAL study. To ensure further patient involvement, we plan to engage the patients in the planning
39 phase of disseminating the results.
40
41
42
43
44
45
46
47
48
49

50 51 **DISCUSSION** 52

53 To the best of our knowledge, the present study will be the largest study evaluating and testing a novel
54 screening procedure for cognitive impairment and emotional reactions during hospitalisation in a population
55 of OHCA survivors. As the incidence of cardiac arrest survival is increasing, establishing a standardized
56 approach to screening in OHCA survivors will be critical in the future. Following the aims of the study and
57
58
59
60

1
2
3 to strengthen the standardization of the results, only patients with a presumed cardiac cause for their cardiac
4
5 arrest as defined by Utstein template will be included. Since a common single etiology of cardiac arrest is
6
7 respiratory failure, it could be considered to include this population in a future study. Although cognitive and
8
9 mental health outcomes in OHCA survivors may be comparable to other medical populations (7,64,65), the
10
11 study does not contain a comparative arm as it does not aim to investigate a specific intervention. Instead the
12
13 study seeks to investigate OHCA survivors after standard treatment in a naturalistic setting. Due to the nature
14
15 of the study and the vulnerable state of the patients, differential loss to follow-up is expected in the study. To
16
17 elucidate data missing not at random, we plan to conduct phone calls to non-responders at 3-months follow-
18
19 up regarding their withdrawal from the study. We expect that results from the REVIVAL study will inform
20
21 an early screening procedure of OHCA survivors in clinical settings as well as inform future targeted
22
23 rehabilitation in survivors who are likely to develop protracted cognitive impairment and psychopathology.
24
25
26
27

28 **ETHICS AND DISSEMINATION**

29
30
31 There is little to no discomfort for the patients and their relatives in this study. Due to the weakened
32
33 constitution of the patients, the neuropsychological test at 3-months post-arrest could be experienced as
34
35 taxing and can be divided into two days. The study complies with the Declaration of Helsinki and has been
36
37 approved by the Danish national committee on health research ethics (H-18046155) and the Danish Data
38
39 Protection Agency (RH-2017-325, I-Suite no: 05961). Patients and their relatives will receive oral and
40
41 written information about the study and inclusion will require obtained written consent for all participants
42
43 before enrolment. Results from this study will be disseminated at regional, national and international
44
45 conferences and in peer-reviewed journals.
46
47
48
49

50 **Authors' contributions**

51
52 Department of Cardiology, Centre for Cardiac, Vascular, Pulmonary and Infectious Diseases, Copenhagen
53
54 University Hospital Rigshospitalet (MKW, SKB, and CH) and Neurobiology Research Unit, Rigshospitalet
55
56 (DSS, PMF and GMK) has full access to all the data in the study and takes responsibility for the integrity of
57
58 data. MKW, SKB, CH and DSS contributed to the study concept and design. MKW, SKB, CH, SA, JEM,
59
60

1
2
3 PMF, GMK and DSS contribute to the data acquisition. Analysis will be performed by MKW, SKB, CH, OE
4
5 and DSS, MKW and DSS drafted the manuscript with critical input from SKB, CH, SA, JEM, OE, TBR,
6
7 PMF and GMK. All authors approved the final version of the manuscript.
8
9

10 11 **Funding statement**

12
13 The REVIVAL study is funded by independent research grants from the following non-profit or
14
15 governmental agencies: The Research Foundation of Copenhagen University Hospital, Rigshospitalet,
16
17 Denmark (GNT 38-A2015 and GNT A5638), The Danish Knowledge Centre for Rehabilitation and
18
19 Palliative Care (REHPA) (GNT 34 177 058), The Helsefonden, Denmark (GNT 18-B-0235), The Danish
20
21 Heart Association (GNT 18-R124-A8454-22099, and from both The Research Committee and the Research
22
23 Committee in clinical nursing, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Denmark
24
25 (GNT Not Applicable).
26
27
28
29

30 31 **Competing interest statement**

32
33 On behalf of all authors, the corresponding author states that there are no conflicts of interest related to this
34
35 study. The funding sources have no role in the design and conduct of the study.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Porzer M, Mrazkova E, Homza M. et. al. Out-of-hospital cardiac arrest. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.* 2017;161(4):348–53.
2. Myat A, Song KJ, Rea T. Out-of-hospital cardiac arrest: current concepts. *Lancet.* 2018;391(10124):970–9.
3. Berdowski J, Berg RA, Tijssen JGP. et. al. Global incidences of out-of-hospital cardiac arrest and survival rates : Systematic review of 67 prospective studies. *Resuscitation.* 2010;81(11):1479–87.
4. Elliott VJ, Rodgers DL, Brett SJ. Systematic review of quality of life and other patient-centred outcomes after cardiac arrest survival. *Resuscitation.* 2011 Mar;82(3):247–56.
5. Green CR, Botha JA, Tiruvoipati R. Review Cognitive function, quality of life and mental health in survivors of out-of-hospital cardiac arrest : a review. *Anaesth Intensive Care.* 2015;43(5):568–77.
6. Moolaert VRMP, Verbunt JA, Van Heugten CM, Wade DT. Cognitive impairments in survivors of out-of-hospital cardiac arrest : A systematic review. *Resuscitation.* 2016;80(2009):297–305.
7. Cronberg T, Lilja G, Horn J, Kjaergaard J, Wise MP, Pellis T. et al. Neurologic Function and Health-Related Quality of Life in Patients Following Targeted Temperature Management at 33°C vs 36°C After Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. *JAMA Neurol.* 2015;72:634–41.
8. Whitehead L, Perkins GD, Clarey A, Haywood KL. A systematic review of the outcomes reported in cardiac arrest clinical trials: The need for a core outcome set. *Resuscitation.* 2015;88:150–7.
9. Perez C, Samudra N, Aiyagari V. Cognitive and Functional Consequence of Cardiac Arrest. *Curr Neurol Neurosci Rep.* 2016;16:70.
10. Sakusic A, O'Horo JC, Dziadzko M, Volha D, Ali R, Singh TD. et al. Potentially Modifiable Risk Factors for Long-Term Cognitive Impairment After Critical Illness: A Systematic Review. *Mayo Clin Proc.* 2018;93(1):68–82.
11. Davies SE, Rhys M, Voss S, Greenwood R, Thomas M, Bengner JR. Psychological wellbeing in survivors of cardiac arrest, and its relationship to neurocognitive function. *Resuscitation.* 2017; Feb;111:22-25.
12. Wachelder EM, Moolaert VRMP, Van Heugten CM. Life after survival : Long-term daily functioning and quality of life after an out-of-hospital cardiac arrest. *Resuscitation.* 2009;80:517–22.
13. Descatha A, Dumas F, Bougouin W, Cariou A, Geri G. Work factors associated with return to work in out-of-hospital cardiac arrest survivors. *Resuscitation.* 2018;128:170–4.
14. Lilja G, Nielsen N, Bro-Jeppesen J, Dunford H, Friberg H, Hofgren C. et al. Return to Work and Participation in Society After Out-of-Hospital Cardiac Arrest. *Circ Cardiovasc Qual Outcomes.* 2018;11(1):e003566.
15. Van Wijnen HGFM, Rasquin SMC, Van Heugten CM, Verbunt JA, Moolaert VRM. The impact of cardiac arrest on the long-term wellbeing and caregiver burden of family caregivers: A prospective cohort study. *Clin Rehabil.* 2017;31(9):1267–75.
16. Cronberg T, Lilja G. Cognitive decline after cardiac arrest - It is more to the picture than hypoxic brain injury. *Resuscitation.* 2015;91(2015):A3–4.
17. Van Heugten C, Gregório GW, Wade D. Evidence-based cognitive rehabilitation after acquired brain injury : A systematic review of content of treatment. *Neuropsychological Rehabilitation.* 2012;22(5):

- 653-73.
18. Mêdrzycka-Dabrowska WA, Czyz-Szybenbejl K, Kwiecień-Jagus K, Lewandowska K. Prediction of cognitive dysfunction after resuscitation-a systematic review. *Postep w Kardiol Interwencyjnej*. 2018;14(3):225–32.
 19. Moulaert VRM, Van Heugten C, Winkens B. et al. Early neurologically-focused follow-up after cardiac arrest improves quality of life at one year: A randomised controlled trial. *Int J Cardiol*. 2015;193.
 20. Barkhof F, Haller S, Rombouts SARB. Resting-State Functional MR Imaging: A New Window to the Brain. *Radiology*. 2014;272(1):29–49.
 21. Nolan JP, Soar J, Cariou A. et al. European Resuscitation Council and European Society of Intensive Care Medicine Guidelines for Post-resuscitation Care 2015: Section 5 of the European Resuscitation Council Guidelines for Resuscitation 2015. *Resuscitation*. 2015;95:202–22.
 22. Hinduja A, Gupta H, Yang JD. et al. Hypoxic ischemic brain injury following in hospital cardiac arrest - Lessons from autopsy. *J Forensic Leg Med*. 2014;23(2014):84–6.
 23. Whitfield-Gabrieli S, Nieto-Castanon A. Conn: A Functional Connectivity Toolbox for Correlated and Anticorrelated Brain Networks. *Brain Connect*. 2012;2(3):125–41.
 24. Vilchinsky N, Ginzburg K, Fait K, Foa EB. Cardiac-disease-induced PTSD (CDI-PTSD): A systematic review. *Clin Psychol Rev*. 2017;55:92–106.
 25. Gamper G, Willeit M, Sterz F, Herkner H, Zoufaly A, Hornik K, et al. Life after death: Posttraumatic stress disorder in survivors of cardiac arrest - Prevalence, associated factors, and the influence of sedation and analgesia. *Crit Care Med*. 2004;32(2):378–83.
 26. Kamphuis HCM, De Leeuw JRJ, Derksen R, Hauer R, Winnubst JAM. A 12-month quality of life assessment of cardiac arrest survivors treated with or without an implantable cardioverter defibrillator. *Europace*. 2002;4(4):417–25.
 27. Moulaert V, Wachelder E, Verbunt J, Wade D, Van Heugten C. Determinants of quality of life in survivors of cardiac arrest. *J Rehabil Med*. 2010;42(6):553–8.
 28. Wilder Schaaf KP, Artman LK, Peberdy MA, Walker WC, Ornato JP, Gossip MR. et al. Anxiety, depression, and PTSD following cardiac arrest: A systematic review of the literature. *Resuscitation*. 2013;84(7):873–7.
 29. Edmondson D, Richardson S, Falzon L, Davidson KW, Mills MA, Neria Y. Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syndrome patients: A meta-analytic review. *PLoS One*. 2012;7(6).
 30. Visser E, Gosens T, Den Oudsten BL, De Vries J. The course, prediction, and treatment of acute and posttraumatic stress in trauma patients. *J Trauma Acute Care Surg*. 2017;82(6):1158–83.
 31. Bryant, RA, Moulds ML, Guthrie RM. Acute Stress Disorder Scale: A Self-Report Measure of Acute Stress Disorder. *Psychol Assess*. 2000;12(1):61–8.
 32. Wessa, M, Rohleder N, Kirschbaum C, Flor H. Altered cortisol awakening response in posttraumatic stress disorder. *Psychoneuroendocrinology*. 2006;31(2):209–15.
 33. Van Wijnen HGFM, Rasquin SMC, Van Heugten CM, Verbunt JA, Moulaert VRM. The impact of cardiac arrest on the long-term wellbeing and caregiver burden of family caregivers: A prospective cohort study. *Clin Rehabil*. 2017;31(9):1267–75.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

34. Zimmerli M, Tisljar K, Balestra GM. et al. Prevalence and risk factors for post-traumatic stress disorder in relatives of out-of-hospital cardiac arrest patients. *Resuscitation*. 2014;85(6):801-8.
35. Haywood K, Dainty KN. Life after cardiac arrest: The importance of engaging with the “forgotten patient.” *Resuscitation*. 2018;128:A1–2.
36. Moulaert V. Life after survival of a cardiac arrest: The brain is the heart of the matter. 2014.
37. Van't Wout Hofland J, Moulaert V, Van Heugten C. et al. Long-term quality of life of caregivers of cardiac arrest survivors and the impact of witnessing a cardiac event of a close relative. *Resuscitation*. 2018;128:198–203.
38. Perkins GD, Jacobs IG, Nadkarni VM, Berg RA, Bhanji F, Biarent D. et al. Cardiac Arrest and Cardiopulmonary Resuscitation Outcome Reports : Update of the Utstein Resuscitation Registry Templates for Out-of-Hospital Cardiac Arrest A Statement for Healthcare Professionals From a Task Force of the International Liaison Committee . *Resuscitation*. 2016;96(2015):328–40.
39. Vandembroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. *PLoS Med*. 2007;4(10):1628–54.
40. Czyż-Szyphenbejl K, Mędrzycka-Dąbrowska W, Sak-Dankosky N. Neurocognitive Testing—Do We Lack in Expertise? *Crit Care Med*. 2019;47(6):e530–1.
41. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA : A Brief Screening. *J Am Geriatr Soc*. 2005;695–9.
42. Boyce LW, Goossens PH, Moulaert VR, Pound G, Van Heugten CM. Out-of-hospital cardiac arrest survivors need both cardiological and neurological rehabilitation! *Curr Opin Crit Care*. 2019;25(3):240–3.
43. Bellelli G, Morandi A, Davis DHJ, Mazzola P, Turco R, Gentile S. et al. Validation of the 4AT, a new instrument for rapid delirium screening: A study in 234 hospitalised older people. *Age Ageing*. 2014;43(4):496–502.
44. Hsueh I-P, Lin J-H, Jeng J-S, Hsieh C-L. Comparison of the psychometric characteristics of the functional independence measure, 5 item Barthel index, and 10 item Barthel index in patients with stroke. *J Neurol Neurosurg Psychiatry*. 2002;73(2):188–90.
45. www.fil.ion.ucl.ac.uk/spm/.
46. Raicle ME. The Brain's Default Mode Network. *Annu Rev Neurosci*. 2015;(38):433–47.
47. Snaith RP. The Hospital Anxiety And Depression Scale. *Health Qual Life Outcomes*. 1983;1(6):29.
48. Creamer M, Bell R, Failla S. Psychometric properties of the Impact of Event Scale - Revised. *Behav Res Ther*. 2003;41(12):1489–96.
49. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *J Psychosom Res*. 2002;Feb;52(2):69–77.
50. Bryant, RA, Harvey AG., Dang ST, Sackville T. Assessing Acute Stress Disorder: Psychometric Properties of a Structured Clinical Interview. *Psychol Assess*. 1998;10(3):215–20.
51. American Psychiatric, *Diagnosis and statistical manual of mental disorders, DSM-5*. 5 th. American Psychiatric Association. Washington, DC; 2013.
52. Bryant RA, Friedman MJ, Spiegel D, Ursano R, Strain J. A review of acute stress disorder in DSM-5.

- 1
2
3 Depress Anxiety. 2011;28(9):802–17.
4
- 5 53. Jensen CG, Hjordt LV, Stenbæk DS, Andersen E, Back SK, Lansner J. et al. Development and
6 psychometric validation of the verbal affective memory test. *Memory*. 2016;24(9):1208–23.
7
- 8 54. Delis DC, Kaplan E, Kramer JH. Delis-Kaplan executive function system. In: The Psychological
9 Corporation. San Antonio, TX; 2001.
- 10
- 11 55. Somerville J, Tremont G, Stern RA. The Boston Qualitative Scoring System as a Measure of
12 Executive Functioning in Rey- Osterrieth Complex Figure Performance. 2010;3395(200010).
13
- 14 56. Wechsler DW. Adult Intelligence Scale. Third edit. San Antonio, TX: The Psychological
15 Corporation; 1997.
- 16
- 17 57. Lyng E, Sandegaard JL, Rebolj M. The Danish National Patient Register. *Scand J Public Heal*.
18 2011;39(7):30–3.
- 19
- 20 58. Pedersen CB. The Danish Civil Registration System. *Scand J Public Heal*. 2011;39(7):22–5.
- 21
- 22 59. Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescription registry. *Scand J Public*
23 *Health*. 2011;39(7):38–41.
- 24
- 25 60. Jensen VM, Rasmussen AW. Danish Education Registers. *Scand J Public Heal*. 2011;39(7):91–4.
- 26
- 27 61. Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. *Scand J Public*
28 *Health*. 2011;39(7):103–5.
- 29
- 30 62. Wechsler D. WAIS-III administration and scoring manual. Antonio, TX Psychol Corp. 1997;
- 31
- 32 63. Weiss DS, Marmar CR. The Impact of Event Scale-Revised. In: Assessing psychological trauma and
33 PTSD: A practioners handbook. New York: Guilford Press; 1997. p. 399–411.
- 34
- 35 64. Jackson JC, Girard TD, Gordon SM, Thompson JL, Shintani AK, Thomason JWW. et al. Long-term
36 cognitive and psychological outcomes in the awakening and breathing controlled trial. *Am J Respir*
37 *Crit Care Med*. 2010;182(2):183–91.
- 38
- 39 65. Cronberg T, Lilja G, Rundgren M, Friberg H, Widner H. Long-term neurological outcome after
40 cardiac arrest and therapeutic hypothermia. *Resuscitation*. 2009;80(10):1119–23.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: The cognitive assessment

The cognitive assessment		
	During hospitalisation	3-months follow up
Target cognitive domain	MoCA	Neuropsychological tests
Attention	Number sequence Letter list	D2 (visual attention) (Trail-making + stroop)
Visuospatial construction	Cube copying	Rey's figure
Episodic memory	Verbal memory test	VAMT-26
Working memory	Serial subtraction	Letter-number sequence
Executive functioning	Trail making B Clock drawing Abstraction	Trailmaking B D-KEFS colour-word interference
Psychomotor Processing speed	Trail making B	Trail making A and B
Language	Naming Repeating Word mobilization	
Orientation	Orientation	

Table 2: Outcome domains, measurement instruments, time of measurement and quantity for the cardiac arrest survivors

Outcome domains, measurement instruments, time of measurement and quantity for the cardiac arrest survivors		
Outcome domains and measurement instruments	Time of measure	Type of quantity
Sociodemographic variables		
Age	T0	Continuous
Sex	T0	Binary
Marital status, type of occupation, employment status, living situation	T0	Categorical
Medical variables		
Known IHD, hypertension, previous MI, PCI or CABG, chronic heart failure, diabetes mellitus, COPD and chronic kidney disease	T0	Binary
Clinical variables related to the cardiac arrest		
Place of OHCA, aetiology of cardiac arrest, initial rhythm, TTM, medication during ICU stay, LVEF	T0	Categorical
Bystander witnessed cardiac arrest, bystander performed CPR, Use of AED, shockable rhythm, awake at arrival to hospital, TTM, intubated, medication during ICU, delirium at ICU	T0	Binary
Time to ROSC, intubation time, length of stay at ICU	T0	Continuous
Conscious state GCS	T0	Categorical
Neurological outcome CPC	T1	Categorical
Length of stay at hospital	T1	Continuous
Performance based variables		
Delirium score 4AT	T1	Categorical
Functional independence Barthel Index- 20	T1	Categorical
Cognitive status MoCA	T1	Binary
Brain activity while resting rsfMRI	T1	Continuous
Neuropsychological outcome VAMT-26, D- KEFS trail-taking, D-KEFS colour-word interference, D-KEFS design fluency, Rey's complex figure and Letter-number sequencing: sub-test of WAIS-IV	T2	Binary
Cortisol Awakening response	T1	Continuous
Patient-reported outcome measures		
POMS	T1	
HADS, IES-R, CSS	T1, T2	Continuous
B-IPQ, FSS, HeartQoL, SF-12, PSQI, CISS, BRIEF-A, ECR-R, AMCQ, CES-S, MTEQ, PTGQ, ACQ, NDEQ	T2	Continuous
Lifestyle changes, Health profile	T2	Categorical
Register based		
Depression, anxiety, dementia, chronic fatigue syndrome and heart failure, mortality and health care utilisation	T3	Continuous

T0: Pre-arrest, medical and clinical data, T1: During hospitalisation, T2: 3 months follow-up, T3: 1 year follow-up

ICU: Intensive Care Unit, **LVEF:** Left Ventricular Ejection Fraction, **OHCA:** Out-of-hospital Cardiac Arrest, **CPR:** Cardiopulmonary resuscitation, **AED:** Automated External Defibrillator, **ROSC:** Return of spontaneous circulation, **TTM:** Targeted Temperature Management, **IHD:** Ischemic Heart Disease, **MI:** Myocardial infarction, **PCI:** Percutaneous coronary Intervention, **CABG:** Coronary Artery Bypass Surgery, **COPD:** Chronic Obstructive Pulmonary Disease, **GCS:** Glasgow Coma Scale, **CPC:** Cerebral Performance Category, **MoCA:** Montreal Cognitive Assessment, **rsfMRI:** resting state functional magnetic resonance imaging, **VAMT-26:** Danish Affective Verbal Learning Test-26, **D- KEFS:** Delis-Kaplan Executive Function System, **POMS:** Profile of Mood States, **HADS:** Hospital Anxiety and Depression Scale, **IES-R:** Impact of Event- Revised, **CSS:** Crisis Support Scale, **B-IPQ:** Brief Illness Perception Scale, **FSS:** Fatigue Severity Scale, **SF-12:** 12-item short Form Survey, **PSQI:** Pittsburgh Sleep Quality Inventory, **CISS:** Coping Inventory for Stressful Situations, **BRIEF-A:** Behavior Rating Inventory of Executive Functions, adult version, **ECR-R:** Experience in close relationships, **AMCQ:** Autobiographical Memory Characteristics Questionnaire, **CES-S:** Centrality of Events – Short, **MTEQ:** Memory of Event Scale, **PTGQ:** Post Traumatic Growth Questionnaire, **ACQ:** Attribution, **NDEQ:** Near-death Experience Questionnaire,

Table 3: Outcome domains, measurement instruments and measurement time for the relatives

Outcome domains, measurement instruments and measurement time for the relatives		
Outcome domain	Measurement instruments	Time
Demographic variables and psychiatric medical history		T2
Health-related quality of life	SF-12	
Anxiety and Depression	HADS	
Distress caused by a traumatic event	IES-R	
Experience in close relationships	ECR-R	
Social support after a crisis	CSS	
Major depression	MDI	
The extent to which an event is viewed as being central to one's identity	CES-S	
Cognitive decline reported by informants (relatives or close friends)	IQ-CODE	

T2: 3 months follow-up

SF-12: 12-item Short Form Survey, **HADS:** Hospital Anxiety and Depression Scale, **IES-R:** Impact of Event- Revised, **ECR-R:** Experience in close relationships, **CSS:** The Crisis Support Scale, **MDI:** Major Depression Inventory, **CES-S:** Centrality of Event short, **IQ-CODE:** The Informant Questionnaire on Cognitive Decline in the Elderly.




Figure 1: Flowchart of study assessment

T₀: Study inclusion, **T₁:** During hospitalisation, **T₂:** 3 months follow-up, **T₃:** 1-year follow-up

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2
Direct patient-feed back

279x82mm (96 x 96 DPI)

Supplementary material 1: Description of secondary outcomes

Sleep quality

The Pittsburgh Sleep Quality Inventory (**PSQI**) is a 19-item measure which assesses sleep quality and disturbances over the last months. The items generate a seven-component score each weighted equally on a 0-3 scale. The sum of these scores provides a global score. Higher scores indicate worse sleep quality. A cut-off score of >5 indicates poor sleep quality (64). The PSQI has demonstrated internal consistency reliability with Cronbach's α 0.83 (65).

Fatigue

Fatigue Severity Scale (**FSS**) is a nine-item questionnaire that measures experienced severity of fatigue symptoms in daily activities on a seven-point scale. A mean score is calculated (range 1–7) with higher scores reflecting greater fatigue. The FSS has shown construct validity with correlation coefficient of 0.68 with the visual analogue scale as external criterion and a Cronbach's α of 0.90 in stroke patients (66).

Executive functioning

Behaviour Rating Inventory of Executive Function (**BRIEF-A**) is a nine-item measure suitable for assessing adults executive functioning in everyday life. BRIEF-A measures different aspects of the executive functioning which are part of three overall clinical indices; *behavioral regulation*, *metacognition* and *general executive function*. Among others the BRIEF-A has been shown sensitive to assess executive function deficiencies in adults with a traumatic brain injury (67). The instrument has shown high internal consistency in clinical populations with a Cronbach's α ranging from 0.93 to 0.96 (68).

Health-related quality of life

The Medical Outcomes Study 12-item Short Form Health Survey (**SF-12**) is an abbreviated version of the SF-36 and a generic health-related quality of life measure. SF-12 measures eight domains of health on 2 domains, respectively physical health and mental health. The scores ranges from 0-10 with higher scores indicating a higher level of health-related quality of life (69). The instrument has been extensively validated in several populations and has shown good reliability when used in a stable coronary population (70).

Quality of life

The **Heart-QoL** is a 14-item heart disease-specific questionnaire that measures the Quality of life in cardiac patients. The scale is divided into a global, physical (10 items) and emotional (four items) component. Items are answered on a four-point Likert scale (range 0–3) with higher scores indicating better HRQoL. Heart-QoL has shown satisfactory internal consistency Cronbach's $\alpha > 0.90$ in Danish implantable cardioverter defibrillator recipients (71).

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.	Relevant text from manuscript
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	Title page and abstract	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract page 3	
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	page 5-7	
Objectives	3	State specific objectives, including any prespecified hypotheses	page 6-7	
Methods				
Study design	4	Present key elements of study design early in the paper	page 7-8	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	page 7-12	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	page 11-13	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	page 9-13	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	page 8-13	
Bias	9	Describe any efforts to address potential sources of bias	page 7-8	
Study size	10	Explain how the study size was arrived at	page 13	

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	page 13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	page 13
Results			N/A
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	

Continued on next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

page 15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.